

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:15 / Search time 21 Seconds
(without alignments)
767.640 Million cell updates/sec

Title: US-09-623-035-2
Perfect score: 2064
Sequence: 1 MTVARPSVPAALPLGELPR.....HTCFTLTGLTLVTMGLLT 381

Scoring table: BLOSUM62

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 157478

Minimum DB seq length: 6
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued Patents AA:
1: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
2: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
3: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
4: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
5: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
6: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	124	6.0	23	1	US-07-811-048-8
2	96	4.7	27	6	5256642-18
3	96	4.7	27	6	5472939-18
4	50.5	2.4	27	2	US-08-541-7598-5
5	48	2.3	26	1	US-08-450-360-12
6	47.5	2.3	27	2	US-08-541-7598-4
7	47.5	2.3	29	4	US-09-043-731-23
8	47	2.3	8	1	US-08-210-266A-4
9	47	2.3	8	1	US-08-688-675-4
10	47	2.3	8	3	US-08-477-860C-4
11	47	2.3	27	2	US-08-169-8488-22
12	47	2.3	27	2	US-08-448-873-22
13	47	2.3	27	2	US-08-382-452D-22
14	47	2.3	27	4	US-08-507-362A-10
15	46.5	2.3	26	2	US-08-288-059-2
16	46	2.2	27	2	US-08-541-7598-3
17	45	2.2	10	6	5378464-24
18	45	2.2	22	6	5378464-8
19	45	2.2	24	3	US-08-701-382-8
20	45	2.2	24	4	US-08-788-820-8
21	44.5	2.2	25	1	US-07-966-187-4
22	44.5	2.2	25	1	US-08-371-121-3
23	44.5	2.2	25	3	US-07-927-391-5
24	44.5	2.2	25	3	US-07-927-391-5
25	44	2.1	25	5	PCT-US94-04361-32
26	44	2.1	22	4	US-09-461-325-488
27	43.5	2.1	22	6	PCT-US94-04361-33

28	43.5	2.1	22	6	5472939-15	Patent No. 5472939
29	43.5	2.1	23	2	US-08-833-807-2	Sequence 2, Appl
30	43.5	2.1	23	3	US-09-223-043-2	Sequence 2, Appl
31	43.5	2.1	23	4	US-09-593-870A-2	Sequence 2, Appl
32	43	2.1	14	6	5256642-19	Patent No. 5256642
33	43	2.1	14	6	5472939-19	Patent No. 5472939
34	43	2.1	19	2	US-08-648-298-16	Sequence 16, Appl
35	43	2.1	25	4	US-09-439-313-520	Sequence 520, App
36	43	2.1	27	3	US-09-071-710-39	Sequence 39, Appl
37	43	2.1	27	3	US-09-525-397-39	Sequence 39, Appl
38	43	2.1	27	4	US-09-439-313-566	Sequence 566, App
39	43	2.1	29	4	US-09-439-313-546	Sequence 546, App
40	42	2.0	7	1	US-08-210-266A-5	Sequence 5, Appl
41	42	2.0	7	1	US-08-688-675-5	Sequence 5, Appl
42	42	2.0	7	3	US-08-477-860C-5	Sequence 39, Appl
43	41.5	2.0	16	1	US-08-151-219-1	Sequence 1, Appl
44	41.5	2.0	16	5	PCT-US94-13205-1	Sequence 1, Appl
45	41.5	2.0	25	5	PCT-US94-04361-34	Sequence 34, Appl

ALIGNMENTS

RESULT 1
US-07-811-048-8
Sequence 8, Application US/07811048
Patent No. 5264357
GENERAL INFORMATION:
APPLICANT: Carab, Ingrid W.
TITLE OF INVENTION: Nucleic Acid and Methods for the Synthesis of No. 5264357el Fu
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: patin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/811,048
FILING DATE: 19911219
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 06/738171
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 06/859107
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US86/01177
APPLICATION NUMBER: 07/083757
ATTORNEY/AGENT INFORMATION:
NAME: Benson, Robert H.
REGISTRATION NUMBER: 30,446
REFERENCE/DOCKET NUMBER: 330p1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415/266-1489
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 amino acids
TYPE: AMINO ACID
TOPOLOGY: linear
US-07-811-048-8
Query Match 6.0%; Score 124; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.1e-05;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

This Page Blank (uspto)

Tue Nov 18 08:04:59 2003

us-09-623-035-2.rat

Page 2

QY 35 DCGLPDPVPAQALERTSPP 56
Db 1 DCGLPDPVPAQALERTSPP 22

1, 11, 13, 34
055, 264, 357

RESULT 2

5256642-18
PATENT NO. 5256642
APPLICANT: PARON, DOUGLAS T.; KICKSTEIN, LLOYD B.; WONG,
MINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
H.; MAKRIDES, SAVVAS; MARSH, HENRY C. JR.
TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
RECEPTOR 1 (CR1) AND A THROMBOTIC AGENT, AND THE METHODS OF
USE THEREOF

NUMBER OF SEQUENCES: 30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/588,128

FILING DATE: 24-SEP-1990

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 412,745

FILING DATE: 26-SEP-1989

APPLICATION NUMBER: 332,865

FILING DATE: 03-APR-1989

APPLICATION NUMBER: 176,532

FILING DATE: 01-APR-1988

SEQ ID NO: 18

LENGTH: 27

5256642-18

Query Match 4.7%; Score 96; DB 6; Length 27;
Best Local Similarity 61.5%; Pred. No. 0.017;
Matches 16; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 257 FTMIGHSITCTVNDGEGSGPPE 282
Db 2 FELVGEPSITCTSDNDVGISGPAQ 27

RESULT 3

5472939-18

PATENT NO. 5472939
APPLICANT: FEARON, DOUGLAS T.; KICKSTEIN, LLOYD B.; WONG,
MINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
H.; MAKRIDES, SAVVAS; MARSH, HENRY C. JR.
TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
MEDIATED DISORDERS

NUMBER OF SEQUENCES: 30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/138,825

FILING DATE: 19-OCT-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 588,128

FILING DATE: 24-SEP-1990

APPLICATION NUMBER: 412,745

FILING DATE: 26-SEP-1989

APPLICATION NUMBER: 332,865

FILING DATE: 03-APR-1989

APPLICATION NUMBER: 176,532

FILING DATE: 01-APR-1988

SEQ ID NO: 18

LENGTH: 27

5472939-18

Query Match 4.7%; Score 96; DB 6; Length 27;
Best Local Similarity 61.5%; Pred. No. 0.017;
Matches 16; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY 257 FTMIGHSITCTVNDGEGSGPPE 282
Db 2 FELVGEPSITCTSDNDVGISGPAQ 27

RESULT 4
US-08-541-759B-5
Sequence 5, Application US/08541759B
Patent No. 5861160

GENERAL INFORMATION:

APPLICANT: Quick, Douglas P.

APPLICANT: Welter, Mark W.

APPLICANT: Welter, Joseph

APPLICANT: Welter, Lisa M.

TITLE OF INVENTION: ISOPORA SUIIS VACCINE

NUMBER OF SEQUENCES: 11

CORRESPONDENCE ADDRESS:

ADDRESSEE: Akzo No. 5861160el Patent Dept.

STREET: 1300 Piccard Drive, Suite 206

CITY: Rockville

STATE: Maryland

COUNTRY: USA

ZIP: 20850

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/541,759B

FILING DATE: 10-OCT-1995

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Kleener, Sharon N.

REGISTRATION NUMBER: 36,335

REFERENCE/DOCKET NUMBER: Quick1a

TELECOMMUNICATION INFORMATION:

TELEPHONE: 301-948-9751

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 27 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-541-759B-5

Query Match 2.4%; Score 50.5; DB 2; Length 27;
Best Local Similarity 41.4%; Pred. No. 3.3e+02;
Matches 12; Conservative 4; Mismatches 8; Indels 5; Gaps 1;

QY 292 VPPTVOKPTTVNPTTEVSPTSQKTTKT 320
Db 1 VPPTTEVP-----PTTEVTPPTTEGTPPT 24

RESULT 5

US-08-450-360-12

Sequence 12, Application US/08450360

PATENT NO. 5656457

GENERAL INFORMATION:

APPLICANT: Parkes, Deborah Lynn

APPLICANT: Coates, Stephen Ralph

TITLE OF INVENTION: Herpes Simplex Virus Type 2-Glycoprotein G

TITLE OF INVENTION: Proteins and Polypeptides

NUMBER OF SEQUENCES: 12

CORRESPONDENCE ADDRESS:

ADDRESSEE: Leona L. Lauder

STREET: 6 Mariposa Court

CITY: Tiburon

STATE: California

COUNTRY: USA

ZIP: 94920

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comugen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:11 (Search time 49 seconds
(without alignments)
1234.180 Million cell updates/sec

Title: US-09-623-035-2

Perfect score: 2064

Sequence: 1 MTVARPSVPALPLGLGELPR.....HRCFTLTGLTGLTVMGLLT 381

Scoring table:

BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 436344

Minimum DB seq length: 6

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

A_Geneseq_19Jun03:*

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*

2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*

3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*

4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*

5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*

6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*

7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*

8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*

9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*

10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*

11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*

12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*

13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*

14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*

15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*

16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*

17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*

18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*

19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*

20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*

21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*

22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*

23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	147	7.1	29	15	AAAS0086
2	89.5	4.3	28	23	AAAS0805
3	64.5	3.1	23	18	AAAS1838
4	61	3.0	10	22	AAAS7023
5	58	2.8	10	22	AAAS7081
6	58	2.8	10	22	AAAS7083
7	57	2.8	10	22	AAAS7043
8	55	2.7	10	22	AAAS7037
9	55	2.7	10	22	AAAS7045

10	54	2.6	10	22	AAAS7089	Human complementar
11	52.5	2.5	19	23	AAAS6534	Oestrogen receptor
12	52.5	2.5	19	21	AAU86371	Oestrogen receptor
13	52	2.5	10	22	AAAS6997	Human complementar
14	52	2.5	10	22	AAAS7001	Human complementar
15	52	2.5	10	22	AAAS7015	Human complementar
16	52	2.5	10	22	AAAS7059	Human complementar
17	52	2.5	10	22	AAAS7091	Human complementar
18	51.5	2.5	27	24	ABU07673	Human complementar
19	51	2.5	10	22	AAAS6999	Human complementar
20	51	2.5	10	22	AAAS7003	Human complementar
21	51	2.5	10	22	AAAS7005	Human complementar
22	51	2.5	10	22	AAAS7007	Human complementar
23	51	2.5	10	22	AAAS7009	Human complementar
24	51	2.5	10	22	AAAS7011	Human complementar
25	51	2.5	10	22	AAAS7013	Human complementar
26	51	2.5	10	22	AAAS7017	Human complementar
27	51	2.5	10	22	AAAS7031	Human complementar
28	51	2.5	10	22	AAAS7033	Human complementar
29	51	2.5	10	22	AAAS7041	Human complementar
30	51	2.5	10	22	AAAS7049	Human complementar
31	51	2.5	10	22	AAAS7051	Human complementar
32	51	2.5	10	22	AAAS7053	Human complementar
33	51	2.5	10	22	AAAS7055	Human complementar
34	51	2.5	10	22	AAAS7069	Human complementar
35	51	2.5	10	22	AAAS7071	Human complementar
36	51	2.5	10	22	AAAS7073	Human complementar
37	51	2.5	10	22	AAAS7075	Human complementar
38	51	2.5	10	22	AAAS7077	Human complementar
39	51	2.5	10	22	AAAS7079	Human complementar
40	51	2.5	10	22	AAAS7085	Human complementar
41	51	2.5	10	22	AAAS7093	Human complementar
42	51	2.5	10	22	AAAS7095	Human complementar
43	51	2.5	10	22	AAAS7097	Human complementar
44	51	2.5	10	22	AAAS7105	Human complementar
45	51	2.5	10	22	AAAS7107	Human complementar

ALIGNMENTS.

RESULT 1					
ID	AAAS0086	standard; Protein; 29 AA.			
XX	XX				
AC	AAAS0086;				
DT	25-MAR-2003	(updated)			
DT	27-OCT-1994	(first entry)			
XX	XX				
DE	XX	Decay accelerating factor derived attachment signal.			
KW	XX	Fusion protein; xenograft; transplacental; membrane; transplacental;			
KW	XX	membrane cofactor protein; MCP; decay accelerating factor; DAF; GPI;			
KW	XX	glycophosphatidyl inositol; anchor; intermembrane transfer			
OS	XX	Homo sapiens.			
XX	XX				
FT	XX	Key			
FT	XX	Domain			
XX	XX	Location/Qualifiers			
XX	XX	13..29 /note="C-terminal hydrophobic domain."			
PN	MO9406903-A1				
PD	31-MAR-1994.				
XX	XX				
PF	22-SEP-1993;	93WO-US08889.			
XX	XX				
PR	22-SEP-1992;	92US-0948521.			
XX	XX				
PA	(DNXB-) DNK BIOTHERAPEUTICS INC.				
XX	XX				
PI	Byrne GW, Kooyman DL, Logan JS;				

This Page Blank (uspto)

XX DR WPI; 1994-118454/14.
 XX PT Delivery of proteins, using mobile cell, by intermembrane
 XX transfer - for pre-accommodation of xenogeneic organ transplants
 XX PS Disclosure; Page 43; 104pp; English.
 CC A protein of interest may be delivered to the tissue of a target
 CC animal by providing mobile cells which bear the protein on their
 CC membrane, linked to a glycoposphatidyl inositol (GPI) anchor. The
 CC cells circulate in the target animal, coming into contact with the
 CC tissue and transfer the protein to the tissue by intermembrane
 CC transfer. Intermembrane transfer by this method occurs at a greater
 CC rate than naturally in the animal. This sequence is an attachment
 CC signal derived from decay accelerating factor (DAF). DAF is
 CC naturally GPI linked. Preferably, the protein of interest is
 CC expressed as a fusion product, the fusion protein comprising this
 CC sequence and the protein (or fragment) of interest. The method is
 CC especially useful for modifying pig organs for xenotransplantation
 CC into humans. See AAO58894.
 CC (Updated on 25-MAR-2003 to correct PW field.)
 CC
 CC Sequence 29 AA:
 SQ
 Query Match 7.1%; Score 147; DB 15; Length 29;
 Best Local Similarity 100.0%; Pred. No. 0.00015;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 353 SGTTRLLSGHTCTFLTGLLGLVTWGLLT 381
 DB 1 SGTTRLLSGHTCTFLTGLLGLVTWGLLT 29
 1, 11, 13, 34
 RESULT 2
 AAMS0805
 ID AAMS0805 standard; Peptide; 28 AA.
 AC AAMS0805;
 XX 01-MAY-2002 (first entry)
 DT
 XX Human complement receptor type 1 tryptic peptide 54d.
 DE
 XX Complement receptor type 1; CRI; C3b/C4b receptor; human;
 KW inflammation; myocardial infarction; reperfusion injury;
 KW antiinflammatory; therapy; diagnosis; receptor; purification.
 XX
 OS Homo sapiens.
 XX
 PN US6316604-B1.
 PD 13-NOV-2001.
 XX
 PF 05-JUN-1995; 95US-0463959.
 XX
 PR 03-APR-1989; 89US-0332865.
 PR 06-DEC-1994; 94US-0350238.
 PR 24-FEB-1993; 93US-0026134.
 PR 01-APR-1988; 88US-0176532.
 XX
 PA (AVANT-) AVANT IMMUNOTHERAPEUTICS INC.
 XX
 XX Fearon DT, Klickstein LB, Wong WW, Carson GR, Concino MF, Ip SH;
 PI Makrides SC, Marsh RC;
 DR WPI; 2002-121028/16.
 XX
 Purifying a recombinant soluble complement receptor type 1 molecule or
 fragment, useful for diagnosing or treating disorders associated
 with complement activity, using cation exchange chromatography provides

PS Example; Column 25; 44pp; English.
 XX
 CC The present sequence is that of tryptic peptide 54d of human
 CC erythrocyte C3b/C4b receptor CRI (complement receptor type 1).
 CC The peptide corresponds to amino acids 204-231 and 654-681 of a
 CC full-length CRI sequence (see AAM50797) predicted from isolated cDNA
 CC clones. The invention provides recombinant, soluble CRI polypeptides
 CC that lack the transmembrane domain of the native protein, and methods
 CC of purifying them. CRI polypeptides and nucleic acids have use in
 CC the diagnosis and therapy of disorders involving complement activity
 CC and various immune system or inflammatory disorders. Secreted,
 CC recombinant CRI has been produced in large quantities using CHO host
 CC cells grown in serum-free medium. The purified protein was used to
 CC reduce damage caused by inflammation, and to reduce myocardial
 CC infarct size and prevent reperfusion injury in rats.
 CC
 CC Sequence 28 AA:
 SQ
 Query Match 4.3%; Score 89.5; DB 23; Length 28;
 Best Local Similarity 59.3%; Pred. No. 3.9;
 Matches 16; Conservative 5; Mismatches 5; Indels 1; Gaps 1;
 QY 257 FTWIGHSIYCTVNDDE-GEWSGPPE 282
 DB 2 FELVGEPSIYCTSDNDQVGIWSGPAQ 28
 RESULT 3
 AAM31838
 ID AAM31838 standard; peptide; 23 AA.
 AC AAM31838;
 XX 26-MAR-1998 (first entry)
 DT
 XX Peptide 4 from the short consensus repeat 3 of complement receptor 1.
 DE
 XX Short consensus repeat 3; long homologous repeat A; LHR-A;
 KW complement receptor 1; CRI; complement inhibition;
 KW anti-haemolytic activity; inflammation; thrombotic condition;
 KW inappropriate complement activation; ARDS; Alzheimer's disease.
 XX
 OS Synthetic.
 XX Homo sapiens.
 XX
 PN WO9731944-A1.
 XX 04-SEP-1997.
 PD
 XX 26-FEB-1997; 97WO-EP00994.
 PF
 XX 02-MAR-1996; 96GB-0004518.
 PR
 XX (SMIK) SMITHKLINE BEECHAM PLC.
 PA Edge CM, Mossakowska DEI, Smith RAG;
 XX
 PI WPI; 1997-448630/41.
 DR
 XX Peptide derived from short consensus repeat 3 of human complement
 XX receptor 1 - between amino acids Cys154-Gly186, useful to treat
 PT disorder or disease associated with inflammation or inappropriate
 PT complement activation
 XX
 PS Claim 13; Page 25; 33pp; English.
 CC Synthetic soluble peptides AAM31835-38 are derived from the short
 CC consensus repeat 3 of the long homologous repeat A (LHR-A) of human
 CC complement receptor 1 (CRI). The present peptide is located between
 CC residues 164 and 186. These peptides have functional complement
 CC inhibitory, including anti-haemolytic, activity. Enhanced activity
 CC may be achieved by linking the peptides to a core structure
 CC (e.g. the MAP peptide) to produce a multimeric or chimeric polypeptide.

This Page Blank (uspto)

SOFTWARE: Patentin Release #1.0, Version #1.30 (EBO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,360
FILING DATE: 25-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/129,021
FILING DATE: 29-SEP-1993
ATTORNEY/AGENT INFORMATION:
NAME: Lauder, Leona L.
REGISTRATION NUMBER: 30,863
REFERENCE/DOCKET NUMBER: D-0012.2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-435-2034
TELEFAX: 415-435-0727
GENERAL INFORMATION:
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 26 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-450-360-12

Query Match 2.3%; Score 48; DB 1; Length 26;
Best Local Similarity 41.7%; Pred. No. 5.4e+02;
Matches 10; Conservative 2; Mismatches 12; Indels 0; Gaps 0;

QY 311 PTSOKTTKTTTPNAQATRSTPVS 334
DB 1 PTTTHATPPTTPGQTPPGPAT 24

RESULT 6
US-08-541-759B-4
Sequence 4, Application US/08541759B
Patent No. 5861160
GENERAL INFORMATION:
APPLICANT: Quick, Douglas P.
APPLICANT: Welter, Mark W.
APPLICANT: Welter, Joseph
APPLICANT: Welter, Lisa M.
TITLE OF INVENTION: ISOSPORA SUIIS VACCINE
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Akzo No. 5861160 Patent Dept.
STREET: 1300 Piccard Drive, Suite 206
CITY: Rockville
STATE: Maryland
COUNTRY: USA
ZIP: 20850
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/541,759B
FILING DATE: 10-OCT-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Klesner, Sharon N.
REGISTRATION NUMBER: 36,335
REFERENCE/DOCKET NUMBER: Quick1a
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-948-9751
TELEFAX: 301-948-7400
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: peptide
US-08-541-759B-4

Query Match 2.3%; Score 47.5; DB 2; Length 27;
Best Local Similarity 37.9%; Pred. No. 6.3e+02;
Matches 11; Conservative 5; Mismatches 8; Indels 5; Gaps 1;

QY 292 VPPTVOKPTTVNVPTEVSPTSOKTTTGT 320
DB 1 LPPTTEVP-----PTEEVTPTEGETPPT 24

RESULT 7
US-09-043-731-23
Sequence 23, Application US/09043731A
Patent No. 6344203
GENERAL INFORMATION:
APPLICANT: The Austin Research Institute
TITLE OF INVENTION: Mimicking Peptides in Cancer Therapy
FILE REFERENCE: CALA-200
CURRENT APPLICATION NUMBER: US/09/043,731A
NUMBER OF SEQ ID NOS: 26
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 23
LENGTH: 29
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: single
US-09-043-731-23

Query Match 2.3%; Score 47.5; DB 4; Length 29;
Best Local Similarity 48.0%; Pred. No. 7e+02;
Matches 12; Conservative 3; Mismatches 9; Indels 1; Gaps 1;

QY 299 PTTVNVPTTE-VSPISOKTTTKT 322
DB 3 PTTTPISTTWVTPPTPTPTGTPT 27

RESULT 8
US-08-210-266A-4
Sequence 4, Application US/08210266A
Patent No. 5545619
GENERAL INFORMATION:
APPLICANT: Atkinson, John P.
APPLICANT: Hourcade, Dennis
APPLICANT: Krych, Malgorzata
TITLE OF INVENTION: Modified Complement System
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 2800 One Atlantic Center, 1201 West Peachtree
STREET: Street
CITY: Atlanta
STATE: Georgia
COUNTRY: US
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/210,266A
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/695,514
FILING DATE: 03-MAY-1991
ATTORNEY/AGENT INFORMATION:

This Page Blank (uspto)

NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: WU101
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404)873-8794
TELEFAX: (404)873-8795
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-210-266A-4

Query Match 2.3%; Score 47; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 214 SDPLPECR 221
Db 1 SDPLPECR 8 1, 34

RESULT 9
US-08-688-675-4
Sequence 4, Application US/08688675
Patent No. 5719127
GENERAL INFORMATION:
APPLICANT: Atkinson, John P.
APPLICANT: Hourcade, Dennis
APPLICANT: Krych, Malgorzata
TITLE OF INVENTION: Modified Complement System Regulators
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 2800 One Atlantic Center, 1201 West Peachtree
STREET: Street
CITY: Atlanta
STATE: Georgia
COUNTRY: US
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/688,675
FILING DATE: 30-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/210,266
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/695,514
FILING DATE: 03-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: WU101div2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404)873-8794
TELEFAX: (404)873-8795
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-688-675-4

2.3%; Score 47; DB 1; Length 8;

Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 214 SDPLPECR 221
Db 1 SDPLPECR 8

RESULT 10
US-08-477-860C-4
Sequence 4, Application US/08477860C
Patent No. 6010873
GENERAL INFORMATION:
APPLICANT: Atkinson, John P.
APPLICANT: Hourcade, Dennis
APPLICANT: Krych, Malgorzata
TITLE OF INVENTION: Modified Complement System Regulators
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Patrea L. Pabst
STREET: 2800 One Atlantic Center, 1201 West Peachtree
STREET: Street
CITY: Atlanta
STATE: Georgia
COUNTRY: US
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/477,860C
FILING DATE: 7-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/210,266
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/695,514
FILING DATE: 03-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: WU 101 DIV
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404)873-8794
TELEFAX: (404)873-8795
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-477-860C-4

Query Match 2.3%; Score 47; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 214 SDPLPECR 221
Db 1 SDPLPECR 8

RESULT 11
US-08-169-948B-22
Sequence 22, Application US/08169948B
Patent No. 5861271
GENERAL INFORMATION:
APPLICANT: Fowler, Timothy
APPLICANT: Ward, Michael
APPLICANT: Clarkson, Kathleen

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:15 ; Search time 21 Seconds
(without alignments)
767.640 Million cell updates/sec

Title: US-09-623-035-2
Perfect score: 2064
Sequence: 1 MVARPSVPAALPLLGELPR.....HTCFTLTGLLTVMGLLT 381

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 157478

Minimum DB seq length: 6
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/iaa/5A_COMB.pep.*
2: /cgn2_6/prodata/1/iaa/5B_COMB.pep.*
3: /cgn2_6/prodata/1/iaa/6A_COMB.pep.*
4: /cgn2_6/prodata/1/iaa/6B_COMB.pep.*
5: /cgn2_6/prodata/1/iaa/PCITUS_COMB.pep.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	124	6.0	23	1 US-07-811-048-8	Sequence 8, Appli
2	96	4.7	27	6 5256642-18	Patent No. 5256642
3	96	4.7	27	6 5472939-18	Patent No. 5472939
4	50.5	2.4	27	2 US-08-541-759B-5	Sequence 5, Appli
5	48	2.3	26	1 US-08-450-360-12	Sequence 12, Appli
6	47.5	2.3	27	2 US-08-541-759B-4	Sequence 4, Appli
7	47.5	2.3	29	4 US-09-043-731-23	Sequence 23, Appli
8	47	2.3	8	1 US-08-210-266A-4	Sequence 4, Appli
9	47	2.3	8	1 US-08-688-675-4	Sequence 4, Appli
10	47	2.3	8	3 US-08-477-860C-4	Sequence 4, Appli
11	47	2.3	27	2 US-08-169-948B-22	Sequence 22, Appli
12	47	2.3	27	2 US-08-448-873-22	Sequence 22, Appli
13	47	2.3	27	3 US-08-382-452D-22	Sequence 22, Appli
14	47	2.3	27	4 US-08-507-362A-10	Sequence 10, Appli
15	46.5	2.3	26	2 US-08-288-059-2	Sequence 2, Appli
16	46	2.2	27	2 US-08-541-759B-3	Sequence 3, Appli
17	45	2.2	10	6 5378464-24	Patent No. 5378464
18	45	2.2	22	6 5378464-8	Patent No. 5378464
19	45	2.2	24	3 US-08-701-382-8	Sequence 8, Appli
20	45	2.2	24	4 US-08-788-820-8	Sequence 8, Appli
21	44.5	2.2	25	1 US-07-966-187-4	Sequence 4, Appli
22	44.5	2.2	25	1 US-08-371-121-3	Sequence 3, Appli
23	44.5	2.2	25	3 US-07-927-391-5	Sequence 5, Appli
24	44.5	2.2	25	5 PCT-US94-04361-32	Sequence 32, Appli
25	44	2.1	22	4 US-09-461-325-488	Sequence 488, App
26	44	2.1	25	5 PCT-US94-04361-33	Sequence 33, Appli
27	43.5	2.1	22	6 5256642-15	Patent No. 5256642

28	43.5	2.1	22	6 5472939-15	Patent No. 5472939
29	43.5	2.1	23	2 US-08-833-807-2	Sequence 2, Appli
30	43.5	2.1	23	3 US-09-223-043-2	Sequence 2, Appli
31	43.5	2.1	23	4 US-09-593-870A-2	Sequence 2, Appli
32	43	2.1	14	6 5256642-19	Patent No. 5256642
33	43	2.1	14	6 5472939-19	Patent No. 5472939
34	43	2.1	19	2 US-08-848-298-16	Sequence 16, Appli
35	43	2.1	25	4 US-09-439-313-520	Sequence 520, App
36	43	2.1	27	3 US-09-071-710-39	Sequence 39, Appli
37	43	2.1	27	3 US-09-525-397-39	Sequence 39, Appli
38	43	2.1	27	4 US-09-439-313-566	Sequence 566, App
39	43	2.1	29	4 US-09-439-313-546	Sequence 546, App
40	42	2.0	7	1 US-08-210-266A-5	Sequence 5, Appli
41	42	2.0	7	1 US-08-688-675-5	Sequence 5, Appli
42	42	2.0	7	3 US-08-477-860C-5	Sequence 5, Appli
43	41.5	2.0	16	1 US-08-151-219-1	Sequence 1, Appli
44	41.5	2.0	16	5 PCT-US94-13205-1	Sequence 1, Appli
45	41.5	2.0	25	5 PCT-US94-04361-34	Sequence 34, Appli

ALIGNMENTS

RESULT 1

US-07-811-048-8
; Sequence 8, Application US/07811048
; Patent No. 5264357

; GENERAL INFORMATION:
; APPLICANT: Caras, Ingrid W.

; TITLE OF INVENTION: Nucleic Acid and Methods for the Synthesis of No. 5264357e1 Fur
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/811,048
; FILING DATE: 19911219
; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/738171
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/859107

; PRIOR APPLICATION DATA: PCT/US86/01177
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/083757

; ATTORNEY/AGENT INFORMATION:
; NAME: Benson, Robert H.
; REGISTRATION NUMBER: 30,446

; REFERENCE/DOCKET NUMBER: 330p1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/266-1489
; TELEFAX: 415/952-9881

; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear

; US-07-811-048-8

Query Match 6.0%; Score 124; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3.1e-05;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	35	DCGLPPDPVNAQPALEGRTSFF	56
	1	DCGLPPDPVNAQPALEGRTSFF	22

1, 11, 13, 34

RESULT 2
5256642-18
; Patent No. 5256642
; APPLICANT: FEARON, DOUGLAS T.; KLUICKSTEIN, LLOYD B.; WONG,
; WINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
; H.; MAKRIDES, SAVVAS; MARSH, HENRY C. JR.
; TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
; RECEPTOR 1 (CR1) AND A THROMBOLYTIC AGENT, AND THE METHODS OF
; USE THEREOF
; NUMBER OF SEQUENCES: 30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/588,128
; FILING DATE: 24-SEP-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 412,745
; FILING DATE: 26-SEP-1989
; APPLICATION NUMBER: 332,865
; FILING DATE: 03-APR-1989
; APPLICATION NUMBER: 176,532
; FILING DATE: 01-APR-1988
; SEQ ID NO: 18:
; LENGTH: 27
5256642-18

Query Match	4.7%	Score 96;	DB 6;	Length 27;
Best Local Similarity	61.5%;	Pred. No. 0.917;		
Matches 16;	Conservative 4;	Mismatches 6;	Indels 0;	Gaps 0;
QY	257	FTMIGHSIYCTVNNDEGWSGPPPE	282	
		: :		
Db	2	FELVGEPSIYCTSNDDVGIWSGAPQ	27	

RESULT 3
5472939-18
; Patent No. 5472939
; APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WONG,
; WINNETT W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
; H.; MAKRIDES, SAVVAS; MARSH, HENRY C. JR.
; TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
; MEDIATED DISORDERS
; NUMBER OF SEQUENCES: 30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/138,825
; FILING DATE: 19-OCT-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 588,128
; FILING DATE: 24-SEP-1990
; APPLICATION NUMBER: 412,745
; FILING DATE: 26-SEP-1989
; APPLICATION NUMBER: 332,865
; FILING DATE: 03-APR-1989
; APPLICATION NUMBER: 176,532
; FILING DATE: 01-APR-1988
; SEQ ID NO:18:
; LENGTH: 27
5472939-18

Query Match	4.7%	Score 96;	DB 6;	Length 27;
Best Local Similarity	61.5%;	Pred. No. 0.017;		
Matches 16;	Conservative 4;	Mismatches 6;	Indels 0;	Gaps 0;
QY	257	FTWIGHSIYCTVNNDEGEWSGPPPE	282	
		.: : : : : : : : : :		
Db	2	FLVAGPSIYCTSNDDVGWISGPAQ	27	

```

RESULT 4
US-08-541-759B-5
; Sequence 5, Application US/08541759B
; Patent No. 5861160
; GENERAL INFORMATION:
; APPLICANT: Quick, Douglas P.
; APPLICANT: Welter, Mark W.
; APPLICANT: Welter, Joseph
; APPLICANT: Welter, Lisa M.
; TITLE OF INVENTION: ISOSPORA SUIIS VACCINE
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Akzo No. 5861160el Patent Dept.
; STREET: 1300 Piccard Drive, Suite 206
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/541,759B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Klesner, Sharon N.
; REGISTRATION NUMBER: 36,335
; REFERENCE/DOCKET NUMBER: Quickla
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-948-7400
; TELEFAX: 301-948-9751
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-541-759B-5

Query Match 2.4%; Score 50.5; DB 2; Length 27;
Best Local Similarity 41.4%; Pred. No. 3.3e+02;
Matches 12; Conservative 4; Mismatches 8; Indels 5;

QY 292 VPPTVOKPTTVNVPTTEVSPTSQKTTTKT 320
||||:|:||||:|:|
DB 1 VPPTEVP-----PTEEVTPPTEGETPPT 24

RESULT 5
US-08-450-360-12
; Sequence 12, Application US/08450360
; Patent No. 5656457
; GENERAL INFORMATION:
; APPLICANT: Parkes, Deborah Lynn
; APPLICANT: Coates, Stephen Ralph
; TITLE OF INVENTION: Herpes Simplex Virus Type 2-Glycoprotein G
; TITLE OF INVENTION: Herpes Simplex Virus Type 2-Glycoprotein G
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Leona L. Lauder
; STREET: 6 Mariposa Court
; CITY: Tiburon
; STATE: California
; COUNTRY: USA
; ZIP: 94920
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

;; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/450,360
;; FILING DATE: 25-MAY-1995
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/129,021
;; FILING DATE: 29-SEP-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Lauder, Leona L.
;; REGISTRATION NUMBER: 30,863
;; REFERENCE/DOCKET NUMBER: D-0012.2A
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-435-2034
;; TELEFAX: 415-435-0727
;; GENERAL INFORMATION:
;; INFORMATION FOR SEQ ID NO: 12:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 26 amino acids
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
US-08-450-360-12

Query Match 2.3%; Score 48; DB 1; Length 26;
Best Local Similarity 41.7%; Pred. No. 5.4e+02;
Matches 10; Conservative 2; Mismatches 12; Indels 0; Gaps 0;
QY 311 PTSQKTTTTPNAQATSTPVS 334
Db 1 PSTHTATPRTTGPOTTPPGPAT 24

RESULT 6
US-08-541-759B-4
; Sequence 4, Application US/08541759B
; Patent No. 5861160
; GENERAL INFORMATION:
; APPLICANT: Quick, Douglas P.
; APPLICANT: Welter, Mark W.
; APPLICANT: Welter, Joseph
; APPLICANT: Welter, Lisa M.
; TITLE OF INVENTION: ISOSPORA SUIIS VACCINE
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Akzo No. 5861160el Patent Dept.
; STREET: 1300 Piccard Drive, Suite 206
; CITY: Rockville
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20850
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/541,759B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Klesner, Sharon N.
; REGISTRATION NUMBER: 36,335
; REFERENCE/DOCKET NUMBER: Quickla
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-948-7400
; TELEFAX: 301-948-9751
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear

;; MOLECULE TYPE: peptide
US-08-541-759B-4
Query Match 2.3%; Score 47.5; DB 2; Length 27;
Best Local Similarity 37.9%; Pred. No. 6.3e+02;
Matches 11; Conservative 5; Mismatches 8; Indels 5; Gaps 1;
QY 292 VPPTVQKPTTVNVPTTEVSPTSQKTTTKT 320
Db 1 LPPTTEVP-----PTEEVTPPTGETPPT 24
RESULT 7
US-09-043-731-23
; Sequence 23, Application US/09043731A
; Patent No. 6344203
; GENERAL INFORMATION:
; APPLICANT: The Austin Research Institute
; TITLE OF INVENTION: Mimicking Peptides in Cancer Therapy
; FILE REFERENCE: CALA-200
; CURRENT APPLICATION NUMBER: US/09/043,731A
; CURRENT FILING DATE: 1998-06-23
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 23
; LENGTH: 29
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: single
; OTHER INFORMATION: stranded linear peptide
US-09-043-731-23

Query Match 2.3%; Score 47.5; DB 4; Length 29;
Best Local Similarity 48.0%; Pred. No. 7e+02;
Matches 12; Conservative 3; Mismatches 9; Indels 1; Gaps 1;
QY 299 PTTNVVPTTE-VSPTSQKTTTKTTT 322
Db 3 PTTTISITTTVMVTPPTPTGTGTPT 27

RESULT 8
US-08-210-266A-4
; Sequence 4, Application US/08210266A
; Patent No. 5545619
; GENERAL INFORMATION:
; APPLICANT: Atkinson, John P.
; APPLICANT: Hourcade, Dennis
; APPLICANT: Krych, Malgorzata
; TITLE OF INVENTION: Modified Complement System
; TITLE OF INVENTION: Regulators
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center, 1201 West Peachtree.
; STREET: Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: US
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/210,266A
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/695,514
; FILING DATE: 03-MAY-1991
; ATTORNEY/AGENT INFORMATION:

```
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: WU101
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404)873-8794
; TELEFAX: (404)873-8795
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-210-266A-4

Query Match      2.3%; Score 47; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      214 SDPLPECR 221
DB      1 SDPLPECR 8

RESULT 9
US-08-688-675-4
; Sequence 4, Application US/08688675
; Patent No. 5719127
; GENERAL INFORMATION:
; APPLICANT: Atkinson, John P.
; APPLICANT: Hourcade, Dennis
; APPLICANT: Krych, Malgorzata
; TITLE OF INVENTION: Modified Complement System Regulators
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center, 1201 West Peachtree
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: US
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 30-JUN-1996
; PRIOR APPLICATION NUMBER: US 08/688,675
; APPLICATION NUMBER: US 08/210,266
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: WU101 DIV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404)873-8794
; TELEFAX: (404)873-8795
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-688-675-4

Query Match      2.3%; Score 47; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      214 SDPLPECR 221
DB      1 SDPLPECR 8

RESULT 10
US-08-477-860C-4
; Sequence 4, Application US/08477860C
; Patent No. 6010873
; GENERAL INFORMATION:
; APPLICANT: Atkinson, John P.
; APPLICANT: Hourcade, Dennis
; APPLICANT: Krych, Malgorzata
; TITLE OF INVENTION: Modified Complement System Regulators
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center, 1201 West Peachtree
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: US
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 7-JUN-1995
; PRIOR APPLICATION NUMBER: US 08/477,860C
; APPLICATION NUMBER: US 08/210,266
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: WU 101 DIV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404)873-8794
; TELEFAX: (404)873-8795
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; US-08-477-860C-4

Query Match      2.3%; Score 47; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      214 SDPLPECR 221
DB      1 SDPLPECR 8

RESULT 11
US-08-169-948B-22
; Sequence 22, Application US/08169948B
; Patent No. 5861271
; GENERAL INFORMATION:
; APPLICANT: Fowler, Timothy
; APPLICANT: Ward, Michael
; APPLICANT: Clarkson, Kathleen
```


APPLICANT: Collier, Katherine
APPLICANT: Larenas, Edmund
TITLE OF INVENTION: No. 5861271el Cellulase Enzymes and Systems
TITLE OF INVENTION: For Their Expression
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genencor International
STREET: 180 Kimball Way
CITY: South San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/169,948B
FILING DATE: DEC 17 1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Horn, Margaret A.
REGISTRATION NUMBER: 33,401
REFERENCE/DOCKET NUMBER: GC226
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 742-7536
TELEFAX: (415) 742-7217
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-169-948B-22

Query Match 2.3%; Score 47; DB 2; Length 27;
Best Local Similarity 40.9%; Pred. No. 7.1e+02;
Matches 9; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

Qy 311 PTSQKTTTKTTTPNAQATRSTP 332
Db 1 PPPASSTTFSTPRSTSSSP 22

RESULT 12
US-08-448-873-22
Sequence 22, Application US/08448873
Patent No. 5874276
GENERAL INFORMATION:
APPLICANT: Fowler, Timothy
APPLICANT: Ward, Michael
APPLICANT: Clarkson, Kathleen
APPLICANT: Collier, Katherine A.
APPLICANT: Larenas, Edmund
TITLE OF INVENTION: No. 5874276el Cellulase Enzymes and Systems
TITLE OF INVENTION: For Their Expressions
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genencor International
STREET: 180 Kimball Way
CITY: South San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/448,873
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/169,948
FILING DATE: 17-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Stone, Christopher L.
REGISTRATION NUMBER: 35,696
REFERENCE/DOCKET NUMBER: GC226D14
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 742-7555
TELEFAX: (415) 742-7217
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-448-873-22

Query Match 2.3%; Score 47; DB 2; Length 27;
Best Local Similarity 40.9%; Pred. No. 7.1e+02;
Matches 9; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

Qy 311 PTSQKTTTKTTTPNAQATRSTP 332
Db 1 PPPASSTTFSTPRSTSSSP 22

RESULT 13
US-08-382-452D-22
Sequence 22, Application US/08382452D
Patent No. 6268196
GENERAL INFORMATION:
APPLICANT: Fowler, Timothy
APPLICANT: Clarkson, Kathleen A.
APPLICANT: Ward, Michael
APPLICANT: Collier, Katherine D.
APPLICANT: Larenas, Edmund A.
TITLE OF INVENTION: NOVEL CELLULOSE ENZYMES AND SYSTEMS
TITLE OF INVENTION: FOR THEIR EXPRESSION
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genencor International
STREET: 925 Page Mill Road
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/382,452D
FILING DATE: February 1, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Christopher L. Stone
REGISTRATION NUMBER: 36,696
REFERENCE/DOCKET NUMBER: GC226-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 742-7555
TELEFAX: (415) 742-7217
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-382-452D-22

Query Match 2.3%; Score 47; DB 3; Length 27;
Best Local Similarity 40.9%; Pred. No. 7.1e+02;

```

CORRESPONDENCE ADDRESS:
ADDRESS: CUSHMAN DARB Y & CUSHMAN, L.L.P.
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/288,059
FILING DATE: 08-AUG-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: CHAPIN, MARLANA K.
REGISTRATION NUMBER: 35,843
REFERENCE/DOCKET NUMBER: 61137/205204
TELECOMMUNICATION INFORMATION:
TELEPHONE: 802-861-3711
TELEFAX: 202-822-0944
TELEX: 6714627 CUSH
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 26 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-288-059-2
Query Match 2.3%; Score 46.5; DB 2; Length 26;
Best Local Similarity 50.0%; Pred. No. 7.5e+02;
Matches 12; Conservative 2; Mismatches 9; Indels

Qy 299 PTTVVV-PTTEVSPTSQKTTTKT 321
| | | : | | | | |
Db 1 PTTPTTTTIVIPPTPTPTGTT 24

Search completed: November 18, 2003, 07:44:07
Job time : 22 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:11 ; Search time 49 Seconds
(without alignments)
1234.180 Million cell updates/sec

Title: US-09-623-035-2

Perfect score: 2064

Sequence: 1 MVARPSVPAALPLLGELPR.....HTCFTLTGLGLTVWGLLT 381

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 436344

Minimum DB seq length: 6

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_19Jun03.*

```

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	147	7.1	29	15	Decay accelerating
2	89.5	4.3	28	23	Human complement r
3	64.5	3.1	23	18	Peptide 4 from the
4	61	3.0	10	22	Human complementar
5	58	2.8	10	22	Human complementar
6	58	2.8	10	22	Human complementar
7	57	2.8	10	22	Human complementar
8	55	2.7	10	22	Human complementar
9	55	2.7	10	22	Human complementar

10	54	2.6	10	22	AAG97089	Human complementar
11	52.5	2.5	19	21	AAU65634	Oestrogen receptor
12	52.5	2.5	19	23	AAU86371	Oestrogen receptor
13	52	2.5	10	22	AAG96997	Human complementar
14	52	2.5	10	22	AAG97001	Human complementar
15	52	2.5	10	22	AAG97015	Human complementar
16	52	2.5	10	22	AAG97059	Human complementar
17	52	2.5	10	22	AAG97091	Human complementar
18	51.5	2.5	27	24	ABU07673	Human haptoglobin
19	51	2.5	10	22	AAG96999	Human complementar
20	51	2.5	10	22	AAG97003	Human complementar
21	51	2.5	10	22	AAG97005	Human complementar
22	51	2.5	10	22	AAG97007	Human complementar
23	51	2.5	10	22	AAG97009	Human complementar
24	51	2.5	10	22	AAG97011	Human complementar
25	51	2.5	10	22	AAG97013	Human complementar
26	51	2.5	10	22	AAG97017	Human complementar
27	51	2.5	10	22	AAG97031	Human complementar
28	51	2.5	10	22	AAG97033	Human complementar
29	51	2.5	10	22	AAG97041	Human complementar
30	51	2.5	10	22	AAG97049	Human complementar
31	51	2.5	10	22	AAG97051	Human complementar
32	51	2.5	10	22	AAG97053	Human complementar
33	51	2.5	10	22	AAG97055	Human complementar
34	51	2.5	10	22	AAG97069	Human complementar
35	51	2.5	10	22	AAG97071	Human complementar
36	51	2.5	10	22	AAG97073	Human complementar
37	51	2.5	10	22	AAG97075	Human complementar
38	51	2.5	10	22	AAG97077	Human complementar
39	51	2.5	10	22	AAG97079	Human complementar
40	51	2.5	10	22	AAG97085	Human complementar
41	51	2.5	10	22	AAG97093	Human complementar
42	51	2.5	10	22	AAG97095	Human complementar
43	51	2.5	10	22	AAG97097	Human complementar
44	51	2.5	10	22	AAG97105	Human complementar
45	51	2.5	10	22	AAG97107	Human complementar

ALIGNMENTS

RESULT 1
AAR50086
ID AAR50086 standard; Protein; 29 AA.

XX AC AAR50086;

XX DT 25-MAR-2003 (updated)

DT 27-OCT-1994 (first entry)

XX DE Decay accelerating factor derived attachment signal.

XX KW Fusion protein; xenograft; transplantation; membrane; transplamt;

XX KW membrane cofactor protein; MCP; decay accelerating factor; DAF; GPI;

XX KW glycoposphatidyl inositol; anchor; intermembrane transfer.

XX OS Homo sapiens.

XX FH Key

FT Domain

FT Location/Qualifiers

FT 13..29

FT /note= "C-terminal hydrophobic domain."

XX WO9406903-A1.

XX PD 31-MAR-1994.

XX PF 22-SEP-1993; 93WO-US08889.

XX PR 22-SEP-1992; 92US-0948521.

XX PA (DNXB-) DNX BIOTHERAPEUTICS INC.

XX PI Byrne GW, Kooyman DL, Logan JS;

XX DR WPI; 1994-118454/14.

XX PT Delivery of proteins, using mobile cell, by intermembrane

XX PT transfer - for pre-accommodation of xenogeneic organ transplants

XX PS Disclosure; Page 43; 104pp; English.

XX CC A protein of interest may be delivered to the tissue of a target

XX CC animal by providing mobile cells which bear the protein on their

XX CC membranes, linked to a glycosphatidyl inositol (GPI) anchor. The

XX CC cells circulate in the target animal, coming into contact with the

XX CC tissue and transfer the protein to the tissue by intermembrane

XX CC transfer. Intermembrane transfer by this method occurs at a greater

XX CC rate than naturally in the animal. This sequence is an attachment

XX CC signal derived from decay accelerating factor (DAF). DAF is

XX CC naturally GPI linked. Preferably, the protein of interest is

XX CC expressed as a fusion product, the fusion protein comprising this

XX CC sequence and the protein (or fragment) of interest. The method is

XX CC especially useful for modifying pig organs for xenotransplantation

XX CC into humans. See AAQ58894.

XX CC (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 29 AA;

Query Match 7.1%; Score 147; DB 15; Length 29;

Best Local Similarity 100.0%; Pred. No. 0.00015;

Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 353 SGTRLLSGHTCFLLGLGLGLTVMGLLT 381

DB 1 SGTRLLSGHTCFLLGLGLGLTVMGLLT 29

1, 11, 13, 34

RESULT 2

AAW50805

ID AAW50805 standard; Peptide; 28 AA.

AC AAW50805;

XX 01-MAY-2002 (first entry)

DE Human complement receptor type 1 tryptic peptide 54d.

XX Complement receptor type 1; CRI; C3b/C4b receptor; human;

XX inflammation; myocardial infarction; reperfusion injury;

XX antiinflammatory; therapy; diagnosis; receptor; purification.

OS Homo sapiens.

XX US6316604-B1.

PN 13-NOV-2001.

PD 05-JUN-1995; 95US-0463959.

PF 03-APR-1989; 89US-0332865.

PR 06-DEC-1994; 94US-0350238.

PR 24-FEB-1993; 93US-0026134.

PR 01-APR-1988; 88US-0176532.

XX (AVAN-) AVANT IMMUNOTHERAPEUTICS INC.

XX Fearon DT, Klickstein LB, Wong WW, Carson GR, Concino MF, Ip SH;

XX Makrides SC, Marsh HC;

XX WPI; 2002-121028/16.

XX Purifying a recombinant soluble complement receptor type 1 molecule or

XX its fragment, useful for diagnosing or treating disorders associated

XX PT with complement activity, using cation exchange chromatography provides

XX PT molecules

PS Example; Column 25; 44pp; English.

XX The present sequence is that of tryptic peptide 54d of human

XX erythrocyte C3b/C4b receptor CRI (complement receptor type 1).

CC The peptide corresponds to amino acids 204-231 and 654-681 of a

CC full-length CRI sequence (see AAM50797) predicted from isolated cDNA

CC clones. The invention provides recombinant, soluble CRI polypeptides

CC that lack the transmembrane domain of the native protein, and methods

CC of purifying them. CRI polypeptides and nucleic acids have use in

CC the diagnosis and therapy of disorders involving complement activity

CC and various immune system or inflammatory disorders. Secreted,

CC recombinant CRI has been produced in large quantities using CHO host

CC cells grown in serum-free medium. The purified protein was used to

CC reduce damage caused by inflammation, and to reduce myocardial

CC infarct size and prevent reperfusion injury in rats.

XX SQ Sequence 28 AA;

Query Match 4.3%; Score 89.5; DB 23; Length 28;

Best Local Similarity 59.3%; Pred. No. 3.9;

Matches 16; Conservative 5; Mismatches 5; Indels 1; Gaps 1;

QY 257 FTMIGHSIYCTVNDE-GEWSGPPPE 282

DB 2 FELVGPSIYCTSDNDQVINGSPAPQ 28

RESULT 3

AAW31838

ID AAW31838 standard; peptide; 23 AA.

XX AAW31838;

XX 26-MAR-1998 (first entry)

DE Peptide 4 from the short consensus repeat 3 of complement receptor 1.

XX Short consensus repeat 3; long homologous repeat A; LHR-A;

XX complement receptor 1; CRI; complement inhibition;

XX anti-haemolytic activity; inflammation; thrombotic condition;

XX inappropriate complement activation; ARDS; Alzheimer's disease.

OS Synthetic.

OS Homo sapiens.

XX WO9731944-A1.

PN 04-SEP-1997.

PD 26-FEB-1997; 97WO-BF00994.

PF 02-MAR-1996; 96GB-0004518.

PR (SMIK) SMITHKLINE BEECHAM PLC.

XX Edge CM, Mossakowska DEI, Smith RAG;

XX WPI; 1997-448630/41.

XX Peptide derived from short consensus repeat 3 of human complement

XX receptor 1 - between amino acids Cys154-Gly186, useful to treat

XX disorder or disease associated with inflammation or inappropriate

XX complement activation

XX Claim 13; Page 25; 33pp; English.

XX Synthetic soluble peptides AAW1835-38 are derived from the short

XX consensus repeat 3 of the long homologous repeat A (LHR-A) of human

XX complement receptor 1 (CRI). The present peptide is located between

XX residues 164 and 186. These peptides have functional complement

XX inhibitory, including anti-haemolytic, activity. Enhanced activity

XX may be achieved by linking the peptides to a core structure

XX (e.g. the MAP peptide) to produce a multimeric or chimeric polypeptide.

CC This polypeptide can be used to treat a disorder or disease associated
 CC with inflammation or inappropriate complement activation. It can also be
 CC used to treat a thrombotic condition, adult respiratory distress
 CC syndrome (ARDS), wounds, Alzheimer's disease or a CNS inflammatory
 CC disorder, or delay hyperacute allograft or xenograft rejection.

XX Sequence 23 AA;

Query Match 3.1%; Score 64.5; DB 18; Length 23;
 Best Local Similarity 56.5%; Pred. No. 2.6e+02;
 Matches 13; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

QY 257 FTWIGHSIIYCTVNNDE-GEWSG 278
 DB 1 FELVGEPSIIYSTNDDQVGWSG 23

RESULT 4

AAG97023
 ID AAG97023 standard; Peptide; 10 AA.

XX AC AAG97023;

XX DT 18-SEP-2001 (first entry)

XX DE Human complementary peptide, SEQ ID NO: 3217.

XX KW Human; complementary peptide; ligand; drug discovery; drug design.

XX OS Homo sapiens.

XX PN WO200142277-A2.

XX PD 14-JUN-2001.

XX PF 13-DEC-2000; 2000WO-GB04776.

XX PR 13-DEC-1999; 99GB-0029464.

XX PA (PROT-) PROTEOM LTD.

XX PI Roberts GW, Heal JR;

XX DR WPI; 2001-408419/43.

XX PT A set of peptide ligands consisting of specific complementary peptides
 XX to proteins encoded by genes of the human genome, useful in an assay
 XX for screening and identifying of one or more novel peptides which are
 XX drug candidates or pro-drugs -

XX PS Example 4; Page 506; 646pp; English.

XX CC The invention relates to a set of complementary peptide ligands
 XX generated from the human genome. The complementary peptides
 XX interact with their relevant target proteins encoded in the human
 XX genome. They can be used as reagents in drug discovery and as lead
 XX ligands to facilitate drug design and development. The present
 XX sequence is a complementary peptide provided in the specification.

XX SQ Sequence 10 AA;

Query Match 3.0%; Score 61; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 278 GPPPECRGKS 287

DB 1 GPPPECRGKS 10

RESULT 5

AAG97081

ID AAG97081 standard; Peptide; 10 AA.

XX AC AAG97081;

XX DT 18-SEP-2001 (first entry)

XX DE Human complementary peptide, SEQ ID NO: 3275.

XX KW Human; complementary peptide; ligand; drug discovery; drug design.

XX OS Homo sapiens.

XX PN WO200142277-A2.

XX PD 14-JUN-2001.

XX PF 13-DEC-2000; 2000WO-GB04776.

XX PR 13-DEC-1999; 99GB-0029464.

XX PA (PROT-) PROTEOM LTD.

XX PI Roberts GW, Heal JR;

XX DR WPI; 2001-408419/43.

XX PT A set of peptide ligands consisting of specific complementary peptides
 XX to proteins encoded by genes of the human genome, useful in an assay
 XX for screening and identifying of one or more novel peptides which are
 XX drug candidates or pro-drugs -

XX PS Example 4; Page 514; 646pp; English.

XX CC The invention relates to a set of complementary peptide ligands
 XX generated from the human genome. The complementary peptides
 XX interact with their relevant target proteins encoded in the human
 XX genome. They can be used as reagents in drug discovery and as lead
 XX ligands to facilitate drug design and development. The present
 XX sequence is a complementary peptide provided in the specification.

XX SQ Sequence 10 AA;

Query Match 2.8%; Score 58; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 2.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 151 WSTAVEFCCK 160

DB 1 WSTAVEFCCK 10

RESULT 6

AAG97083

ID AAG97083 standard; Peptide; 10 AA.

XX AC AAG97083;

XX DT 18-SEP-2001 (first entry)

XX DE Human complementary peptide, SEQ ID NO: 3277.

XX KW Human; complementary peptide; ligand; drug discovery; drug design.

XX OS Homo sapiens.

XX PN WO200142277-A2.

XX PD 14-JUN-2001.

XX PF 13-DEC-2000; 2000WO-GB04776.

XX PR 13-DEC-1999; 99GB-0029464.

XX PA (PROT-) PROTEOM LTD.

```

XX PI Roberts GW, Heal JR;
XX DR WPI; 2001-408419/43.
XX
XX A set of peptide ligands consisting of specific complementary peptides
XX PT to proteins encoded by genes of the human genome, useful in an assay
XX PT for screening and identifying of one or more novel peptides which are
XX PT drug candidates or pro-drugs -
XX
XX Example 4; Page 514; 646pp; English.
XX
XX The invention relates to a set of complementary peptide ligands
XX CC generated from the human genome. The complementary peptides
XX CC interact with their relevant target proteins encoded in the human
XX CC genome. They can be used as reagents in drug discovery and as lead
XX CC ligands to facilitate drug design and development. The present
XX CC sequence is a complementary peptide provided in the specification.
XX
XX Sequence 10 AA;
XX
XX Query Match 2.8%; Score 58; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 2.8e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 361 GHTCFTLTGL 370
XX DB 1 GHTCFTLTGL 10
XX
XX RESULT 7
XX AAG97043
XX ID AAG97043 standard; Peptide; 10 AA.
XX AC AAG97043;
XX DT 18-SEP-2001 (first entry)
XX DE Human complementary peptide, SEQ ID NO: 3337.
XX
XX Human; complementary peptide; ligand; drug discovery; drug design.
XX
XX Homo sapiens.
XX
XX WO200142277-A2.
XX
XX 14-JUN-2001.
XX
XX PF 13-DEC-2000; 2000WO-GB04776.
XX
XX PR 13-DEC-1999; 99GB-0029464.
XX
XX PA (PROT-) PROTEOM LTD.
XX
XX PI Roberts GW, Heal JR;
XX
XX WPI; 2001-408419/43.
XX
XX A set of peptide ligands consisting of specific complementary peptides
XX PT to proteins encoded by genes of the human genome, useful in an assay
XX PT for screening and identifying of one or more novel peptides which are
XX PT drug candidates or pro-drugs -
XX
XX Example 4; Page 508; 646pp; English.
XX
XX The invention relates to a set of complementary peptide ligands
XX CC generated from the human genome. The complementary peptides
XX CC interact with their relevant target proteins encoded in the human
XX CC genome. They can be used as reagents in drug discovery and as lead
XX CC ligands to facilitate drug design and development. The present
XX CC sequence is a complementary peptide provided in the specification.
XX
XX Sequence 10 AA;
XX
XX Query Match 2.8%; Score 55; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 4.7e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 247 QSVTYACNKG 256
XX DB 1 QSVTYACNKG 10
XX
XX RESULT 9
XX AAG97045
XX ID AAG97045 standard; Peptide; 10 AA.
XX AC AAG97045;
XX DT 18-SEP-2001 (first entry)
XX DE Human complementary peptide, SEQ ID NO: 3239.
XX
XX Sequence 10 AA;

```

```

XX Query Match 2.8%; Score 57; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 3.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 123 TVVEYECRPG 132
XX DB 1 TVVEYECRPG 10
XX
XX RESULT 8
XX AAG97037
XX ID AAG97037 standard; Peptide; 10 AA.
XX AC AAG97037;
XX DT 18-SEP-2001 (first entry)
XX DE Human complementary peptide, SEQ ID NO: 3231.
XX
XX Human; complementary peptide; ligand; drug discovery; drug design.
XX
XX Homo sapiens.
XX
XX WO200142277-A2.
XX
XX 14-JUN-2001.
XX
XX PF 13-DEC-2000; 2000WO-GB04776.
XX
XX PR 13-DEC-1999; 99GB-0029464.
XX
XX PA (PROT-) PROTEOM LTD.
XX
XX PI Roberts GW, Heal JR;
XX
XX WPI; 2001-408419/43.
XX
XX A set of peptide ligands consisting of specific complementary peptides
XX PT to proteins encoded by genes of the human genome, useful in an assay
XX PT for screening and identifying of one or more novel peptides which are
XX PT drug candidates or pro-drugs -
XX
XX Example 4; Page 508; 646pp; English.
XX
XX The invention relates to a set of complementary peptide ligands
XX CC generated from the human genome. The complementary peptides
XX CC interact with their relevant target proteins encoded in the human
XX CC genome. They can be used as reagents in drug discovery and as lead
XX CC ligands to facilitate drug design and development. The present
XX CC sequence is a complementary peptide provided in the specification.
XX
XX Sequence 10 AA;
XX
XX Query Match 2.7%; Score 55; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 4.7e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 247 QSVTYACNKG 256
XX DB 1 QSVTYACNKG 10
XX
XX RESULT 9
XX AAG97045
XX ID AAG97045 standard; Peptide; 10 AA.
XX AC AAG97045;
XX DT 18-SEP-2001 (first entry)
XX DE Human complementary peptide, SEQ ID NO: 3239.
XX
XX Sequence 10 AA;

```

KW Human; complementary peptide; ligand; drug discovery; drug design.
 OS Homo sapiens.
 PN WO200142277-A2.
 PD 14-JUN-2001.
 XX 13-DEC-2000; 2000WO-GB04776.
 XX 13-DEC-1999; 99GB-0029464.
 PA (PROT-) PROTEOM LTD.
 XX Roberts GW, Heal JR;
 DR WPI; 2001-408419/43.
 PT A set of peptide ligands consisting of specific complementary peptides
 PT to proteins encoded by genes of the human genome, useful in an assay
 PT for screening and identifying of one or more novel peptides which are
 PT drug candidates or pro-drugs -
 XX
 PS Example 4; Page 509; 646pp; English.
 XX The invention relates to a set of complementary peptide ligands
 CC generated from the human genome. The complementary peptides
 CC interact with their relevant target proteins encoded in the human
 CC genome. They can be used as reagents in drug discovery and as lead
 CC ligands to facilitate drug design and development. The present
 CC sequence is a complementary peptide provided in the specification.
 XX
 SQ Sequence 10 AA;
 Query Match 2.7%; Score 55; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 4.7e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 358 LLSGHTCFTL 367
 DB 1 LLSGHTCFTL 10
 RESULT 10
 AAG97089
 ID AAG97089 standard; Peptide; 10 AA.
 AC AAG97089;
 XX 18-SEP-2001 (first entry)
 DE Human complementary peptide, SEQ ID NO: 3283.
 XX Human; complementary peptide; ligand; drug discovery; drug design.
 OS Homo sapiens.
 PN WO200142277-A2.
 PD 14-JUN-2001.
 XX 13-DEC-2000; 2000WO-GB04776.
 XX 13-DEC-1999; 99GB-0029464.
 PA (PROT-) PROTEOM LTD.
 XX Roberts GW, Heal JR;
 DR WPI; 2001-408419/43.
 XX A set of peptide ligands consisting of specific complementary peptides
 PT to proteins encoded by genes of the human genome, useful in an assay

PT for screening and identifying of one or more novel peptides which are
 PT drug candidates or pro-drugs -
 XX
 PS Example 4; Page 515; 646pp; English.
 XX The invention relates to a set of complementary peptide ligands
 CC generated from the human genome. The complementary peptides
 CC interact with their relevant target proteins encoded in the human
 CC genome. They can be used as reagents in drug discovery and as lead
 CC ligands to facilitate drug design and development. The present
 CC sequence is a complementary peptide provided in the specification.
 XX
 SQ Sequence 10 AA;
 Query Match 2.6%; Score 54; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 5.7e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 291 KVPPTVQKPT 300
 DB 1 KVPPTVQKPT 10
 RESULT 11
 AAY65634
 ID AAY65634 standard; Peptide; 19 AA.
 AC AAY65634;
 XX 01-FEB-2000 (first entry)
 DE Oestrogen receptor beta ERE binding peptide 29E-beta.
 XX Oestrogen receptor; estrogen; estradiol; oestrogen response element;
 KW ERE; binding; biological activity; fingerprint; molecular braille;
 KW cellular braille; modulation; tamoxifen; breast cancer; ovarian cancer;
 KW menopause; osteoporosis; selective oestrogen receptor modulator;
 KW identification; characterisation; classification.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9954728-A2.
 PN 28-OCT-1999.
 PD 26-MAR-1999; 99WO-US06664.
 XX 23-APR-1998; 98US-0082756.
 PR 09-SEP-1998; 98US-0099656.
 PR 08-JAN-1999; 99US-0115345.
 XX (NOVA-) NOVALON PHARM CORP.
 PA Paige LA, Hamilton PT, Fowlkes DM, Buehrer B, Barnett T;
 PI McDonnell DP, Christensen DJ;
 XX WPI; 2000-013281/01.
 PT Methods for identifying new receptor modulators, especially estrogen
 PT modulators to treat tamoxifen refractory breast cancer -
 XX
 PS Example 2.2; Page 165; 219pp; English.
 XX The present invention describes a method for predicting the biological
 CC activity of new receptor modulating compounds (I) using novel oligomeric
 CC peptides (biokeys) which have differential abilities to bind to 2
 CC different receptor conformations. The method is used to identify new
 CC drugs that are physiological or pharmacological agonists/antagonists and
 CC that target various receptors, which are involved in certain disease
 CC conditions. The system may be used as a primary screening tool to
 CC identify hits, to classify lead compounds from a drug screen to,
 CC characterise selective oestrogen receptor modulators (SERMs) in terms of

agonist and antagonist function and to predict possible clinical effects of SRMs such as tissue and receptor specificity. The method can also be applied to the fractionation of mixtures of SRMs to determine which components are producing agonistic and antagonistic activity. The method may be used with other receptors (e.g. progesterone, dopamine and glucocorticoid, thyroid, vitamin D, beta-adrenergic, dopamine and epidermal growth factor, to identify, characterise and classify modulators of receptor activity. Peptides comprising a LXXLL motif may be used to modulate the oestrogen receptor in treating e.g. breast and ovarian cancer and ameliorating the effects of menopause, including osteoporosis. AAY65439 to AAY65652 represent oestrogen receptor, estradiol receptor and oestrogen response element binding peptides given in the exemplification of the present invention. AA235740 to AA235745 represent oligonucleotides used in the exemplification of the present invention.

XX SQ Sequence 19 AA;
Query Match 2.5%; Score 52.5; DB 21; Length 19;
Best Local Similarity 47.6%; Pred. No. 1.7e+03;
Matches 10; Conservative 1; Mismatches 5; Indels 5; Gaps 1;

QY 209 SSVQSDPLPEGREIYCPAPP 229
||| :| :|||
Db 1 SSYDW-----QCPSWYCPAPP 16

RESULT 12
AAU86371
ID AAU86371 standard; Peptide; 19 AA.

AC AAU86371;
XX
XX 21-MAY-2002 (first entry)
DT
XX Oestrogen receptor beta binding peptide 29E-beta.
DE
XX Oestrogen receptor; breast cancer; combinatorial peptide library;
KW receptor modulating compound.
XX Synthetic.

OS
XX WO200204956-A2.
XX 17-JAN-2002.

XX 11-JUL-2001; 2001WO-US21867.

XX 12-JUL-2000; 2000US-0614865.

PR 21-MAY-2001; 2001US-0860688.

XX (KARO-) KARO BIO USA INC.

PA Fowlkes DM, Barnett TR, Buehrer B;

PI WPI; 2002-154969/20.

DR
XX Identifying receptor-binding peptides comprises screening combinatorial peptide library presented in form of cells each of which coexpress one peptide member and receptor with signal producing system for reporting binding

XX Disclosure; Page 147; 175pp; English.

XX The invention relates to identifying a binding peptide which binds a receptor and which is a member of a combinatorial library of peptides, comprising screening a combinatorial peptide library presented in the form of cells which coexpress the receptor or its ligand-binding receptor moiety and one member of the library, together with a signal producing system for reporting binding of the peptide to the receptor. Also included is a method for predicting the receptor-modulating activity of a compound which modulates the biological activity of a receptor comprising (a) identifying peptides which bind the receptor by the

CC method above, (b) using a number of the peptides to predict the receptor-modulating activity of a compound by (i) providing a panel of identified peptides, where the members differ in their ability to bind to the receptor depending on reference conformations the receptor is in, where the effect of a number of reference substances known to modulate the biological activity of the receptor on the binding of each member of the panel is known and is characterised as a reference fingerprint for each reference substance, (ii) screening a test substance of unknown activity relative to the receptor to determine its effect on the binding of each member of the panel to the receptor, thereby obtaining a test fingerprint for the test substance, (iii) comparing the test fingerprint to the reference fingerprints and (iv) predicting the biological activity of the test substance based on the assumption that its biological activity will be similar to that of reference substances with similar fingerprints. The method is useful for identifying a binding peptide which binds a vertebrate, mammalian, preferably human receptor, an intracellular, nuclear, oestrogen or androgen receptor. The identified peptides which bind to the receptor are useful for predicting the receptor-modulating activity of a compound (e.g. ant/agonists). The receptor-binding library members are useful in the prediction of the ability of small organic molecules, suitable for pharmaceutical use (e.g. in the case of oestrogen receptors, for breast cancer treatment), to interact with the receptor. The analyte-binding molecules can also be used for in vivo imaging. The method has several advantages over whole animal-based assay systems in that the same technology can be applied to a variety of different receptors, the system can be used for high throughput screening and compound characterisation, and gives very distinct patterns for agonists and antagonists of receptor activity using very much less protein. The present sequence is an oestrogen receptor binding peptide from a combinatorial peptide library.

XX SQ Sequence 19 AA;

Query Match 2.5%; Score 52.5; DB 23; Length 19;
Best Local Similarity 47.6%; Pred. No. 1.7e+03;
Matches 10; Conservative 1; Mismatches 5; Indels 5; Gaps 1;

QY 209 SSVQSDPLPEGREIYCPAPP 229
||| :| :|||
Db 1 SSYDW-----QCPSWYCPAPP 16

RESULT 13

AAG96997

ID AAG96997 standard; Peptide; 10 AA.

XX AAG96997;

XX 18-SEP-2001 (first entry)

DE Human complementary peptide, SEQ ID NO: 3191.

XX Human; complementary peptide; ligand; drug discovery; drug design.

XX Homo sapiens.

XX WO200142277-A2.

XX 14-JUN-2001.

XX 13-DEC-2000; 2000WO-GB04776.

XX 13-DEC-1999; 99GB-0029464.

XX (PROT-) PROTEOM LTD.

XX Roberts GW, Heal JR;

XX WPI; 2001-408419/43.

XX A set of peptide ligands consisting of specific complementary peptides to proteins encoded by genes of the human genome, useful in an assay for screening and identifying of one or more novel peptides which are

PT drug candidates or pro-drugs -

PS Example 4; Page 502; 646pp; English.

XX The invention relates to a set of complementary peptide ligands
CC generated from the human genome. The complementary peptides
CC interact with their relevant target proteins encoded in the human
CC genome. They can be used as reagents in drug discovery and as lead
CC ligands to facilitate drug design and development. The present
CC sequence is a complementary peptide provided in the specification.

XX Sequence 10 AA;

Query Match 2.5%; Score 52; DB 22; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 196 LFGSTSSFCFL 205

Db 1 LFGSTSSFCFL 10

RESULT 14

AAG97001

ID AAG97001 standard; Peptide; 10 AA.

AC AAG97001;

XX 18-SEP-2001 (first entry)

XX Human complementary peptide; ligand; drug discovery; drug design.

XX Homo sapiens.

OS WO200142277-A2.

XX 14-JUN-2001.

XX 13-DEC-2000; 2000WO-GB04776.

XX 13-DEC-1999; 99GB-0029464.

XX (PROT-) PROTEOM LTD.

XX Roberts GW, Heal JR;

XX WPI; 2001-408419/43.

XX A set of peptide ligands consisting of specific complementary peptides
PT to proteins encoded by genes of the human genome, useful in an assay
PT for screening and identifying of one or more novel peptides which are
PT drug candidates or pro-drugs -

PS Example 4; Page 503; 646pp; English.

XX The invention relates to a set of complementary peptide ligands
CC generated from the human genome. The complementary peptides
CC interact with their relevant target proteins encoded in the human
CC genome. They can be used as reagents in drug discovery and as lead
CC ligands to facilitate drug design and development. The present
CC sequence is a complementary peptide provided in the specification.

XX Sequence 10 AA;

Query Match 2.5%; Score 52; DB 22; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 316 TTTKTTTTPNA 325

Db 1 TTTKTTTTPNA 10

RESULT 15

AAG97015

ID AAG97015 standard; Peptide; 10 AA.

XX AAG97015;

XX 18-SEP-2001 (first entry)

XX Human complementary peptide; ligand; drug discovery; drug design.

XX Homo sapiens.

XX WO200142277-A2.

XX 14-JUN-2001.

XX 13-DEC-2000; 2000WO-GB04776.

XX 13-DEC-1999; 99GB-0029464.

XX (PROT-) PROTEOM LTD.

XX Roberts GW, Heal JR;

XX WPI; 2001-408419/43.

XX A set of peptide ligands consisting of specific complementary peptides
PT to proteins encoded by genes of the human genome, useful in an assay
PT for screening and identifying of one or more novel peptides which are
PT drug candidates or pro-drugs -

PS Example 4; Page 504; 646pp; English.

XX The invention relates to a set of complementary peptide ligands
CC generated from the human genome. The complementary peptides
CC interact with their relevant target proteins encoded in the human
CC genome. They can be used as reagents in drug discovery and as lead
CC ligands to facilitate drug design and development. The present
CC sequence is a complementary peptide provided in the specification.

XX Sequence 10 AA;

Query Match 2.5%; Score 52; DB 22; Length 10;

Best Local Similarity 100.0%; Pred. No. 8.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 192 TGYKLFSGSTS 201

Db 1 TGYKLFSGSTS 10

Search completed: November 18, 2003, 07:43:38

Job time : 50 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:46 ; Search time 26 Seconds
(without alignments)
1409.241 Million cell updates/sec

Title: US-09-623-035-2

Perfect score: 2064

Sequence: 1 MVARSPVPAALPLLGELPR.....HTCFTLTGLLGLTVTMGLLT 381

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 6074

Minimum DB seq length: 6

Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 76:.*
1: pir1:.*
2: pir2:.*
3: pir3:.*
4: pir4:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	48	2.3	25	2 A48810	fibrinogen B beta
2	41.5	2.0	28	2 I52394	fibronectin, splic
3	40	1.9	26	2 S68302	xanthine dehydrog
4	40	1.9	27	1 TZA23	toxin III - snake-
5	40	1.9	29	2 I78337	copper transportin
6	39	1.9	28	2 I48349	fibronectin - mous
7	38	1.8	24	2 A84023	hypothetical prote
8	38	1.8	26	2 D32248	Ig kappa chain V r
9	38	1.8	26	2 A44036	collagen alpha 1(X
10	38	1.8	27	1 PGF1	paragonial peptide
11	37.5	1.8	26	2 S65604	sec c 1 protein -
12	37	1.8	11	2 D45300	complement C3b rec
13	37	1.8	20	2 PC1151	equinotoxin 1C - s
14	37	1.8	20	2 B34016	tenebrosin B - sea
15	37	1.8	28	2 B64669	hypothetical prote
16	36.5	1.8	30	2 S59482	hydroxyproline-ric
17	36	1.7	20	2 PC1150	equinotoxin 1B - s
18	36	1.7	26	2 A61195	reverse transcript
19	36	1.7	27	2 PL0029	plasma protein Po2
20	36	1.7	27	2 A84477	5S ribosomal RNA
21	36	1.7	28	2 E49533	T-cell receptor be
22	36	1.7	30	2 A27103	aspartate transami
23	35.5	1.7	29	2 C61384	tracheal mucin gly
24	35	1.7	18	2 JU0125	polyphemusin II -
25	35	1.7	20	2 A34016	tenebrosin A - sea
26	35	1.7	21	2 S08590	NADH2 dehydrogenas
27	35	1.7	24	2 B49480	major immunophilin
28	35	1.7	25	2 I60083	glycophorin A - hu
29	34.5	1.7	20	2 B41299	T-cell receptor al

30	34.5	1.7	27	2 A47295	homeodomain protei
31	34.5	1.7	27	2 S28940	cyclic nucleotide-
32	34.5	1.7	29	2 A60604	glutathione peroxi
33	34	1.6	11	2 I33098	173K exoantigen -
34	34	1.6	15	2 PT0222	Ig heavy chain CDR
35	34	1.6	16	2 S38292	30K allergen - rye
36	34	1.6	18	2 I52614	u-plasminogen acti
37	34	1.6	19	2 PH1339	Ig heavy chain DJ
38	34	1.6	19	2 B28457	proteoglycan II, b
39	34	1.6	20	2 A61276	superoxide dismuta
40	34	1.6	21	2 I65270	collagen alpha 1(I
41	34	1.6	23	2 E39855	paralytic peptide
42	34	1.6	23	2 D39855	paralytic peptide
43	34	1.6	23	2 D39855	paralytic peptide
44	34	1.6	23	2 B60691	phycobillissome 29K
45	34	1.6	26	1 NTSR3L	neurotoxin III - E

ALIGNMENTS

RESULT 1

A48810
fibrinogen B beta subunit - African clawed frog (fragment)

C;Species: Xenopus laevis (African clawed frog)

C;Date: 07-Apr-1994 #sequence_revision 18-Nov-1994 #text_change 21-Jul-2000

C;Accession: A48810

R;Roberts, L.R.; Nichols, L.A.; Holland, L.J.

Biochemistry 32, 11627-11637, 1993

A;Title: Transcriptional regulation of the Xenopus laevis B beta fibrinogen subunit gene

A;Reference number: A48810; MUID:94032285; PMID:8218230

A;Accession: A48810

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-25 <ROB>

A;Cross-references: GB:U05035; GB:S66373; NID:g450950; PIDN:AAA60463.1; PID:g450951

A;Note: sequence extracted from NCBI backbone (NCBIN:138880, NCBIP:138881)

Query Match 2.3%; Score 48; DB 2; Length 25;
Best Local Similarity 64.3%; Pred. No. 1.9e+03;

Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 20 RLLLVLLCLPAVW 33

Db 2 RVLLLPALCVSAW 15

RESULT 2

I52394

fibronectin, splice form II - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 20-Aug-1999

C;Accession: I52394; I53217

R;Sekiguchi, K.; Klos, A.M.; Kurachi, K.; Yoshitake, S.;

Biochemistry 25, 4936-4941, 1986

A;Title: Human liver fibronectin complementary DNAs: identification of two different mess

A;Reference number: I52394; MUID:87026578; PMID:3021206

A;Accession: I52394

A;Status: preliminary; translated from GB/EMBL/DBDJ

A;Molecule type: mRNA

A;Residues: 1-28 <RES>

A;Cross-references: GB:M14059; NID:g182700; PIDN:AAA52463.1; PID:g182703

R;Kornblitt, A.R.; Vibe-Pedersen, K.; Baralle, F.E.

EMBO J. 3, 221-226, 1984

A;Title: Human fibronectin: Molecular cloning evidence for two mRNA species differing by

A;Reference number: I53217; MUID:84158533; PMID:6200322

A;Accession: I53217

A;Status: preliminary; translated from GB/EMBL/DBDJ

A;Molecule type: mRNA

A;Residues: 3-16 <RE2>

A;Cross-references: GB:K02273; NID:g182698; PIDN:AAA35850.1; PID:g182699

C;Genetics:

A;Gene: GDB:FN1

```
A;Cross-references: GDB:119135; OMIM:135600
A;Map position: 2q34-2q34
C;Superfamily: fibronectin; fibronectin type I repeat homology; fibronectin type II repeat homology; fibronectin type I repeat homology; fibronectin type II repeat homology
C;Keywords: alternative splicing

  Query Match      2.0%; Score 41.5; DB 2; Length 28;
  Best Local Similarity 48.0%; Pred. No. 6.1e+03;
  Matches 12; Conservative 3; Mismatches 5; Indels 5; Gaps 2;

QY 294 PTQKPT-TTVNVPT-...TEVSPTS 313
Db 2 PLVQTAVTTTPAPDLKFTQVTPS 26

RESULT 3
S68902
xanthine dehydrogenase (EC 1.1.1.204) 18.4K chain - Veillonella atypica (fragment)
C;Species: Veillonella atypica
C;Date: 23-Jul-1997 #sequence_revision 29-Aug-1997 #text_change 29-Aug-1997
C;Accession: S68902
R;Gremer, L.; Meyer, O.
A;Title: Characterization of xanthine dehydrogenase from the anaerobic bacterium Veillonella atypica
A;Reference number: S68900; MUID:96300255; PMID:8706691
A;Accession: S68902
A;Molecule type: protein
A;Residues: 1-26 <GRE>
A;Experimental source: DSM 1399
C;Keywords: 2Fe-2S; FAD; flavoprotein; heterotrimer; iron-sulfur protein; metalloprotein

  Query Match      1.9%; Score 40; DB 2; Length 26;
  Best Local Similarity 56.2%; Pred. No. 7.1e+03;
  Matches 9; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 298 KPTVNVPTTEVSPTS 313
Db 10 KNVTNVPTDEMLLT 25

RESULT 4
TZA23
toxin III - snake-locks sea anemone
C;Species: Anemonia sulcata (snake-locks sea anemone)
C;Date: 30-Apr-1979 #sequence_revision 24-Sep-1981 #text_change 04-Oct-1996
C;Accession: A91446; A91674; A01798
R;Martinez, G.; Kopeyan, C.; Schweitz, H.; Lazdunski, M.
FEBS Lett. 84, 247-252, 1977
A;Title: Toxin III from Anemonia sulcata: primary structure.
A;Reference number: A91446; MUID:78084776; PMID:23311
A;Accession: A91446
A;Molecule type: protein
A;Residues: 1-27 <MAR>
R;Berres, L.; Wundt, G.; Wachtel, E.
Hoppe-Seyler's Z. Physiol. Chem. 358, 985-988, 1977
A;Title: Amino acid sequence of toxin III from Anemonia sulcata.
A;Reference number: A91674; MUID:78044787; PMID:21843
A;Accession: A91674
A;Molecule type: protein
A;Residues: 1-21, 'SC', 24-27 <BER>
C;Comment: Three disulfide bonds are present.
C;Superfamily: toxin III
C;Keywords: venom

  Query Match      1.9%; Score 40; DB 1; Length 27;
  Best Local Similarity 26.7%; Pred. No. 7.4e+03;
  Matches 8; Conservative 2; Mismatches 8; Indels 12; Gaps 1;

QY 28 CLPAVWGDCGLPPDPVNAQPALEGRTSFPE 57
Db 3 CCPCYWGCPW-----GQNCYPE 20

RESULT 5
```

```
178537
copper transporting P-type ATPase - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 21-Jul-2000
C;Accession: I78537
R;Thomas, G.R.; Forbes, J.R.; Roberts, E.A.; Walshe, J.M.; Cox, D.W.
Nature Genet. 9, 210-217, 1995
A;Title: The Wilson disease gene: spectrum of mutations and their consequences.
A;Reference number: I58128; MUID:95235569; PMID:7626145
A;Accession: I78537
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-29 <RES>
A;Cross-references: GB:S77450; NID:G957354; PIDN:AAB34087.1; PID:G957355
C;Genetics:
A;Gene: GDB:ATP7B
A;Cross-references: GDB:120494; OMIM:277900
A;Map position: 13q14.3-13q21.1

  Query Match      1.9%; Score 40; DB 2; Length 29;
  Best Local Similarity 31.8%; Pred. No. 8.1e+03;
  Matches 7; Conservative 3; Mismatches 12; Indels 0; Gaps 0;

QY 28 CLPAVWGDCGLPPDPVNAQPAL 49
Db 8 CLPSALSEIQFPADIRQKSPL 29

RESULT 6
I48349
fibronectin - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 20-Aug-1999
C;Accession: I48349; S33445
R;Polly, P.; Nicholson, R.C.
Gene 137, 353-354, 1993
A;Title: Sequence of the mouse fibronectin-encoding gene promoter region.
A;Reference number: I48349; MUID:94131313; PMID:8299972
A;Accession: I48349
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-28 <RES>
A;Cross-references: EMBL:222729; NID:G297911; PIDN:CAA80422.1; PID:G297912
R;Polly, P.; Nicholson, R.C.
Submitted to the EMBL Data Library, May 1993
A;Description: Nucleotide sequence of the murine fibronectin gene promoter region.
A;Reference number: S33445
A;Accession: S33445
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-27 <POL>
A;Cross-references: EMBL:222729
C;Superfamily: fibronectin; fibronectin type I repeat homology; fibronectin type II repeat homology

  Query Match      1.9%; Score 39; DB 2; Length 28;
  Best Local Similarity 80.0%; Pred. No. 9.1e+03;
  Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 20 RLLLVLLCL 29
Db 9 RLLLVLLCL 18

RESULT 7
A84023
hypothetical protein BH2985 [imported] - Bacillus halodurans (strain C-125)
C;Species: Bacillus halodurans
C;Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001
C;Accession: A84023
R;Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hirano, T.
Nucleic Acids Res. 28, 4317-4331, 2000
A;Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A;Reference number: A83650; MUID:20512582; PMID:11058132
```

paragonial peptide PS-1 - fruit fly (*Drosophila funebris*)
 CSpecies: *Drosophila funebris*
 CDate: 13-Jul-1981
 CName: *Drosophila funebris*
 CAccession: A01281
 CReleaseDate: 1981-07-13
 CSequenceRevision: 13-Jul-1981
 CText_1: Ryugo, T.; Wilson, K.J.; Chen, P.S.; Humbel, R.E.
 ETitle: The amino acid sequence of a peptide (PS-1) from
 EAccession: A01281
 EReleaseDate: 1981-07-13
 EText_1: Ryugo, T.; Wilson, K.J.; Chen, P.S.; Humbel, R.E.
 EText_2: Biochem. 55, 521-529, 1975

A;Accession: A01643
A;Molecule type: protein
A;Residues: 1-27 <BAU>
A;Note: 2-leu was found in 30% of the molecules

C;Comment: This peptide, produced in the paragonial (accessory sex) C;Genetics:
A;Gene: FlyBase:Dfun/PapC
A;Cross-references: FlyBase:FBgn0004112

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Figure 1**
 10. **Figure 2**
 11. **Figure 3**
 12. **Figure 4**
 13. **Figure 5**
 14. **Figure 6**
 15. **Figure 7**
 16. **Figure 8**
 17. **Figure 9**
 18. **Figure 10**
 19. **Figure 11**
 20. **Figure 12**
 21. **Figure 13**
 22. **Figure 14**
 23. **Figure 15**
 24. **Figure 16**
 25. **Figure 17**
 26. **Figure 18**
 27. **Figure 19**
 28. **Figure 20**
 29. **Figure 21**
 30. **Figure 22**
 31. **Figure 23**
 32. **Figure 24**
 33. **Figure 25**
 34. **Figure 26**
 35. **Figure 27**
 36. **Figure 28**
 37. **Figure 29**
 38. **Figure 30**
 39. **Figure 31**
 40. **Figure 32**
 41. **Figure 33**
 42. **Figure 34**
 43. **Figure 35**
 44. **Figure 36**
 45. **Figure 37**
 46. **Figure 38**
 47. **Figure 39**
 48. **Figure 40**
 49. **Figure 41**
 50. **Figure 42**
 51. **Figure 43**
 52. **Figure 44**
 53. **Figure 45**
 54. **Figure 46**
 55. **Figure 47**
 56. **Figure 48**
 57. **Figure 49**
 58. **Figure 50**
 59. **Figure 51**
 60. **Figure 52**
 61. **Figure 53**
 62. **Figure 54**
 63. **Figure 55**
 64. **Figure 56**
 65. **Figure 57**
 66. **Figure 58**
 67. **Figure 59**
 68. **Figure 60**
 69. **Figure 61**
 70. **Figure 62**
 71. **Figure 63**
 72. **Figure 64**
 73. **Figure 65**
 74. **Figure 66**
 75. **Figure 67**
 76. **Figure 68**
 77. **Figure 69**
 78. **Figure 70**
 79. **Figure 71**
 80. **Figure 72**
 81. **Figure 73**
 82. **Figure 74**
 83. **Figure 75**
 84. **Figure 76**
 85. **Figure 77**
 86. **Figure 78**
 87. **Figure 79**
 88. **Figure 80**
 89. **Figure 81**
 90. **Figure 82**
 91. **Figure 83**
 92. **Figure 84**
 93. **Figure 85**
 94. **Figure 86**
 95. **Figure 87**
 96. **Figure 88**
 97. **Figure 89**
 98. **Figure 90**
 99. **Figure 91**
 100. **Figure 92**
 101. **Figure 93**
 102. **Figure 94**
 103. **Figure 95**
 104. **Figure 96**
 105. **Figure 97**
 106. **Figure 98**
 107. **Figure 99**
 108. **Figure 100**
 109. **Figure 101**
 110. **Figure 102**
 111. **Figure 103**
 112. **Figure 104**
 113. **Figure 105**
 114. **Figure 106**
 115. **Figure 107**
 116. **Figure 108**
 117. **Figure 109**
 118. **Figure 110**
 119. **Figure 111**
 120. **Figure 112**
 121. **Figure 113**
 122. **Figure 114**
 123. **Figure 115**
 124. **Figure 116**
 125. **Figure 117**
 126. **Figure 118**
 127. **Figure 119**
 128. **Figure 120**
 129. **Figure 121**
 130. **Figure 122**
 131. **Figure 123**
 132. **Figure 124**
 133. **Figure 125**
 134. **Figure 126**
 135. **Figure 127**
 136. **Figure 128**
 137. **Figure 129**
 138. **Figure 130**
 139. **Figure 131**
 140. **Figure 132**
 141. **Figure 133**
 142. **Figure 134**
 143. **Figure 135**
 144. **Figure 136**
 145. **Figure 137**
 146. **Figure 138**
 147. **Figure 139**
 148. **Figure 140**
 149. **Figure 141**
 150. **Figure 142**
 151. **Figure 143**
 152. **Figure 144**
 153. **Figure 145**
 154. **Figure 146**
 155. **Figure 147**
 156. **Figure 148**
 157. **Figure 149**
 158. **Figure 150**
 159. **Figure 151**
 160. **Figure 152**
 161. **Figure 153**
 162. **Figure 154**
 163. **Figure 155**
 164. **Figure 156**
 165. **Figure 157**
 166. **Figure 158**
 167. **Figure 159**
 168. **Figure 160**
 169. **Figure 161**
 170. **Figure 162**
 171. **Figure 163**
 172. **Figure 164**
 173. **Figure 165**
 174. **Figure 166**
 175. **Figure 167**
 176. **Figure 168**
 177. **Figure 169**
 178. **Figure 170**
 179. **Figure 171**
 180. **Figure 172**
 181. **Figure 173**
 182. **Figure 174**
 183. **Figure 175**
 184. **Figure 176**
 185. **Figure 177**
 186. **Figure 178**
 187. **Figure 179**
 188. **Figure 180**
 189. **Figure 181**
 190. **Figure 182**
 191. **Figure 183**
 192. **Figure 184**
 193. **Figure 185**
 194. **Figure 186**
 195. **Figure 187**
 196. **Figure 188**
 197. **Figure 189**
 198. **Figure 190**
 199. **Figure 191**
 200. **Figure 192**
 201. **Figure 193**
 202. **Figure 194**
 203. **Figure 195**
 204. **Figure 196**
 205. **Figure 197**
 206. **Figure 198**
 207. **Figure 199**
 208. **Figure 200**
 209. **Figure 201**
 210. **Figure 202**
 211. **Figure 203**
 212. **Figure 204**
 213. **Figure 205**
 214. **Figure 206**
 215. **Figure 207**
 216. **Figure 208**
 217. **Figure 209**

Query Match 1.8%; Score 38; DB 1; Length 27;
Best Local Similarity 26.9%; Pred. No. 1e+04;
Matches 7; Conservative 7; Mismatches 12; Indels 0;

303 NVPTTEVSPTSOKTTTKTTTPNAOAT 328

Db 1 DVFSANNORTAAKPOVAEAS 26

S65604 sec c 1 protein - rye (fragment)
C;Species: Secale cereale (rye)

```
#sequence_revision 13-Mar-1997 #text_change 13-March-1997
C;Accession: S65604
R;Garcia-Casado, G.;Armentia, A.; Sanchez-Monge, R.; Sanchez-Izquierdo, I.M.;
#sequence_revision 13-Mar-1997 #text_change 13-March-1997
```

FEBS Lett. 364, 36-40, 1995
A>Title: A major baker's asthma allergen from rye flour is considered
A,Reference number: S55604; MUID:95269763; PMID:7750539
A,Accession: S55604

A;status: preliminary
A;Molecule type: protein
A;Residues: 1-26 <GAR>

Best Local Similarity 46.7%; Pred. No. 1.1e+04;

Matches	7;	Conservative	4;	Mismatches	3;	Indels	1;
Qy	208	GSSVQWSDPLPECRE	222				

Db 11 GKSIS-NNVPACRE 24

```
RESULT 12
D45900
complement C3b receptor type 2 - mouse (clone 12) (fragment)
```

C;Species: Mus musculus (house mouse)

C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-MN-
C;Accession: D45900
R;Kurtz, C.B.; O'Toole, E.; Christensen, S.M.; Weis, J.H.

J. Immunol. 144, 3581-3591, 1990
A; Title: The murine complement receptor gene family. IV. Alternative
A; Reference number: A4590; MUID:90229754; PMID:2139460

A; Accession: D43500
A; Status: preliminary; nucleic acid sequence not shown; not compared

A;Molecule type: mRNA
A;Residues: 1-11 <KUR>

Query Match 1.8%; Score 37; DB 2; Length 11;

Best Local Similarity	60.0%;	Pred. No.	4.3e+03;				
Matches	6;	Conservative	0;	Mismatches	4;	Indels	0;

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

Db 2 CEEISCDppp 11

```

RESULT 13
PC1151
equinatoxin 1C - sea anemone (Actinia equina) (fragment)
C:Species: Actinia equina
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 07-May-1999
C/Accession: PC1151
R;Komatsu, S.; Furukawa, K.; Abe, K.; Hirano, H.; Ueda, M.
Chem. Pharm. Bull. 40, 2873-2875, 1992
A>Title: Isolation and characterization of equinatoxins from the sea anemone Actinia equina
A:Reference number: PC1149; MUID:93099631; PMID:1361161
A/Accession: PC1151
A:Molecule type: protein
A:Residues: 1-20 <KOM>
C;Keywords: toxin

Query Match          1.8%   Score 37;  DB 2;  Length 20;
Best Local Similarity 37.5%   Pred. No. 8.5e+03;
Matches 6;  Conservative 6;  Mismatches 4;  Indels 0;  Gaps 0;

QY 174 IDVPGGILFGATISFS 189
Db 2 VAVAGAVIEGATLTEN 17
:| | | | | | | | | |
:| | | | | | | | | |

RESULT 14
B34016
tenebrosin B - sea anemone (Actinia tenebrosa) (fragment)
C:Species: Actinia tenebrosa
C>Date: 15-Jun-1990 #sequence_revision 15-Jun-1990 #text_change 30-Sep-1993
C/Accession: B34016
R;Norton, R.S.; Bobek, G.; Ivanov, J.O.; Thomson, M.; Fiala-Beer, E.; Moritz, R.L.; Simpson, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Watthey, L.
Toxicol 28, 29-41, 1990
A>Title: Purification and characterization of proteins with cardiac stimulatory and haemolytic activity
A:Reference number: A34016; MUID:90232538; PMID:1970442
A/Accession: B34016
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-20 <NOR>

Query Match          1.8%   Score 37;  DB 2;  Length 20;
Best Local Similarity 37.5%   Pred. No. 8.5e+03;
Matches 6;  Conservative 6;  Mismatches 4;  Indels 0;  Gaps 0;

QY 174 IDVPGGILFGATISFS 189
Db 2 VAVAGAVIEGATLTEN 17
:| | | | | | | | | |
:| | | | | | | | | |

RESULT 15
B64669
hypothetical protein HP1194 - Helicobacter pylori (strain 26695)
C:Species: Helicobacter pylori
C>Date: 09-Aug-1997 #sequence_revision 09-Aug-1997 #text_change 08-Oct-1999
C/Accession: B64669
R;Tomb, J.F.; White, O.; Kerlavage, A.R.; Clayton, R.A.; Sutton, G.G.; Fleischmann, R.D.; Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khalak, H.G.; Glodek, A.; McKenney, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Watthey, L.
Nature 388, 539-547, 1997
A:Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.; Fraser, C.
A>Title: The complete genome sequence of the gastric pathogen Helicobacter pylori.
A:Reference number: A64520; MUID:97394467; PMID:9252185
A/Accession: B64669
A>Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-28 <TOM>
A/Cross-references: GB:AE000625; GB:AE000511; MID:g2314349; PID:AAD08244.1; PID:g231435

Query Match          1.8%   Score 37;  DB 2;  Length 28;
Best Local Similarity 36.8%   Pred. No. 1.2e+04;
Matches 7;  Conservative 5;  Mismatches 7;  Indels 0;  Gaps 0;

```

```

QY 130 RPYRREPSLSPKLTCLQN 148
Db 10 RPYKAFRLTNDKLFQIQS 28

```

Search completed: November 18, 2003, 07:49:56
Job time : 29 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:16 ; Search time 243 Seconds
(without alignments)
286.235 Million cell updates/sec

Title: US-09-623-035-2
Perfect score: 2064
Sequence: 1 MVARPSVPAALPLGELPR.....HTCFTLTGLLGLVTMGLLT 381

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 666188 seqs, 182559486 residues

Total number of hits satisfying chosen parameters: 149430

Minimum DB seq length: 6
Maximum DB seq length: 30

Post-Processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA.*

- 1: /cgn2_6/prodata/1/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/prodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/prodata/1/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/prodata/1/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/prodata/1/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/prodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/prodata/1/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/prodata/1/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/prodata/1/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/prodata/1/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/prodata/1/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/prodata/1/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/prodata/1/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/prodata/1/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/prodata/1/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/prodata/1/pubpaa/US10_NEW_PUB.pep.*
- 17: /cgn2_6/prodata/1/pubpaa/US60_NEW_PUB.pep.*
- 18: /cgn2_6/prodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	64.5	3.1	23	10	US-09-142-043-8
2	61	3.0	10	11	Sequence 8, Appli
3	58	2.8	10	11	Sequence 3217, Ap
4	58	2.8	10	11	Sequence 3275, Ap
5	57	2.8	10	11	Sequence 3277, Ap
6	55	2.7	10	11	Sequence 3237, Ap
7	55	2.7	10	11	Sequence 3231, Ap
8	54	2.6	10	11	Sequence 3239, Ap
9	52	2.5	10	11	Sequence 3283, Ap
10	52	2.5	10	11	Sequence 3191, Ap
11	52	2.5	10	11	Sequence 3195, Ap
12	52	2.5	10	11	Sequence 3209, Ap
13	52	2.5	10	11	Sequence 3253, Ap
14	51	2.5	10	11	Sequence 3285, Ap
15	51	2.5	10	11	Sequence 3193, Ap
					Sequence 3197, Ap

16	51	2.5	10	11	US-09-572-404B-3199	Sequence 3199, Ap
17	51	2.5	10	11	US-09-572-404B-3201	Sequence 3201, Ap
18	51	2.5	10	11	US-09-572-404B-3203	Sequence 3203, Ap
19	51	2.5	10	11	US-09-572-404B-3205	Sequence 3205, Ap
20	51	2.5	10	11	US-09-572-404B-3207	Sequence 3207, Ap
21	51	2.5	10	11	US-09-572-404B-3211	Sequence 3211, Ap
22	51	2.5	10	11	US-09-572-404B-3225	Sequence 3225, Ap
23	51	2.5	10	11	US-09-572-404B-3227	Sequence 3227, Ap
24	51	2.5	10	11	US-09-572-404B-3235	Sequence 3235, Ap
25	51	2.5	10	11	US-09-572-404B-3243	Sequence 3243, Ap
26	51	2.5	10	11	US-09-572-404B-3245	Sequence 3245, Ap
27	51	2.5	10	11	US-09-572-404B-3247	Sequence 3247, Ap
28	51	2.5	10	11	US-09-572-404B-3249	Sequence 3249, Ap
29	51	2.5	10	11	US-09-572-404B-3263	Sequence 3263, Ap
30	51	2.5	10	11	US-09-572-404B-3265	Sequence 3265, Ap
31	51	2.5	10	11	US-09-572-404B-3267	Sequence 3267, Ap
32	51	2.5	10	11	US-09-572-404B-3269	Sequence 3269, Ap
33	51	2.5	10	11	US-09-572-404B-3271	Sequence 3271, Ap
34	51	2.5	10	11	US-09-572-404B-3273	Sequence 3273, Ap
35	51	2.5	10	11	US-09-572-404B-3279	Sequence 3279, Ap
36	51	2.5	10	11	US-09-572-404B-3287	Sequence 3287, Ap
37	51	2.5	10	11	US-09-572-404B-3289	Sequence 3289, Ap
38	51	2.5	10	11	US-09-572-404B-3291	Sequence 3291, Ap
39	51	2.5	10	11	US-09-572-404B-3299	Sequence 3299, Ap
40	51	2.5	10	11	US-09-572-404B-3301	Sequence 3301, Ap
41	51	2.5	10	11	US-09-572-404B-3303	Sequence 3303, Ap
42	51	2.5	10	11	US-09-572-404B-3309	Sequence 3309, Ap
43	51	2.5	10	11	US-09-572-404B-3317	Sequence 3317, Ap
44	51	2.5	10	11	US-09-572-404B-3319	Sequence 3319, Ap
45	51	2.5	10	11	US-09-572-404B-3321	Sequence 3321, Ap

ALIGNMENTS

RESULT 1
US-09-142-043-8
; Sequence 8, Application US/09142043
; Patent No. US20020142372A1
; GENERAL INFORMATION:
; APPLICANT: MOSSAKOWSKA, Danuta Ewa Irena
; APPLICANT: EDGE, Colin Michael
; APPLICANT: SMITH, Richard Anthony Godwin
; TITLE OF INVENTION: FRAGMENTS OF CR1 AND THEIR USE
; FILE REFERENCE: 88362/104
; CURRENT APPLICATION NUMBER: US/09/142, 043
; CURRENT FILING DATE: 1998-12-01
; EARLIER APPLICATION NUMBER: WO PCT/EP97/00994
; EARLIER FILING DATE: 1997-02-26
; EARLIER APPLICATION NUMBER: GB 96045182.2
; EARLIER FILING DATE: 1996-03-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-142-043-8

Query Match 3.1%; Score 64.5; DB 10; Length 23;
Best Local Similarity 56.5%; Pred. No. 99;
Matches 13; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

QY 257 FTMIGHSIYCTVNDE-GEWSG 278
| : | | | | | : | : | | |
Db 1 FELVGEPSIYSTNDQVIGWSG 23

RESULT 2
US-09-572-404B-3217
; Sequence 3217, Application US/09572404B
; Publication No. US20030078174A1
; GENERAL INFORMATION:

```
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3217
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 278-287 and may interact with
; OTHER INFORMATION: Sequence 3218 in this patent.
US-09-572-404B-3217

Query Match      3.0%; Score 61; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 278 GPPPECRGKS 287
Db 1 GPPPECRGKS 10

RESULT 3
US-09-572-404B-3275
; Sequence 3275, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3275
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 151-160 and may interact with
; OTHER INFORMATION: Sequence 3276 in this patent.
US-09-572-404B-3275

Query Match      2.8%; Score 58; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 151 WSTAVBFCKK 160
Db 1 WSTAVBFCKK 10

RESULT 4
US-09-572-404B-3277
; Sequence 3277, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3277
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 361-370 and may interact with
```

```
; OTHER INFORMATION: Sequence 3278 in this patent.
US-09-572-404B-3277

Query Match      2.8%; Score 58; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 361 GHTCFTLTGL 370
Db 1 GHTCFTLTGL 10

RESULT 5
US-09-572-404B-3237
; Sequence 3237, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3237
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 123-132 and may interact with
; OTHER INFORMATION: Sequence 3238 in this patent.
US-09-572-404B-3237

Query Match      2.8%; Score 57; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 123 TVVEYECRPG 132
Db 1 TVVEYECRPG 10

RESULT 6
US-09-572-404B-3231
; Sequence 3231, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3231
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 247-256 and may interact with
; OTHER INFORMATION: Sequence 3232 in this patent.
US-09-572-404B-3231

Query Match      2.7%; Score 55; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 247 QSVTYACNKG 256
Db 1 QSVTYACNKG 10

RESULT 7
```


US-09-572-404B-3239
; Sequence 3239, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3239
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 358-367 and may interact with
; OTHER INFORMATION: Sequence 3240 in this patent.
US-09-572-404B-3239
Query Match 2.7%; Score 55; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 358 LLSGHTCFTL 367
Db 1 LLSGHTCFTL 10
RESULT 8
US-09-572-404B-3283
; Sequence 3283, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3283
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 291-300 and may interact with
; OTHER INFORMATION: Sequence 3284 in this patent.
US-09-572-404B-3283
Query Match 2.6%; Score 54; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 291 KVPPTVQKPT 300
Db 1 KVPPTVQKPT 10
RESULT 9
US-09-572-404B-3191
; Sequence 3191, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3191
; LENGTH: 10

; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 196-205 and may interact with
; OTHER INFORMATION: Sequence 3192 in this patent.
US-09-572-404B-3191
Query Match 2.5%; Score 52; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 196 LFGSTSSFCL 205
Db 1 LFGSTSSFCL 10
RESULT 10
US-09-572-404B-3195
; Sequence 3195, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3195
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 316-325 and may interact with
; OTHER INFORMATION: Sequence 3196 in this patent.
US-09-572-404B-3195
Query Match 2.5%; Score 52; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 316 TTKTKTTPNA 325
Db 1 TTKTKTTPNA 10
RESULT 11
US-09-572-404B-3209
; Sequence 3209, Application US/09572404B
; Publication No. US20030078374A1
; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd
; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent
; CURRENT APPLICATION NUMBER: US/09/572,404B
; CURRENT FILING DATE: 2000-05-17
; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0
; SEQ ID NO 3209
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; OTHER INFORMATION: sequence located in DAF OR CD55 at 192-201 and may interact with
; OTHER INFORMATION: Sequence 3210 in this patent.
US-09-572-404B-3209
Query Match 2.5%; Score 52; DB 11; Length 10;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 192 TGYKLFGSTS 201
Db 1 TGYKLFGSTS 201

Db 1 TGVKLFGSTS 10

RESULT 12

US-09-572-404B-3253
; Sequence 3253, Application US/09572404B
; Publication No. US20030078374A1

; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd

; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent

; CURRENT APPLICATION NUMBER: US/09/572,404B

; CURRENT FILING DATE: 2000-05-17

; NUMBER OF SEQ ID NOS: 4203

; SOFTWARE: ProtPatent version 1.0

; SEQ ID NO 3253

; LENGTH: 10

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; OTHER INFORMATION: sequence located in DAF OR CD55 at 330-339 and may interact with
; OTHER INFORMATION: Sequence 3254 in this patent.

US-09-572-404B-3253

Query Match 2.5%; Score 52; DB 11; Length 10;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 330 STPVSRRTTKH 339

Db 1 STPVSRRTTKH 10

|||||

Db 1 STPVSRRTTKH 10

RESULT 13

US-09-572-404B-3285

; Sequence 3285, Application US/09572404B
; Publication No. US20030078374A1

; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd

; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent

; CURRENT APPLICATION NUMBER: US/09/572,404B

; CURRENT FILING DATE: 2000-05-17

; NUMBER OF SEQ ID NOS: 4203

; SOFTWARE: ProtPatent version 1.0

; SEQ ID NO 3285

; LENGTH: 10

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; OTHER INFORMATION: sequence located in DAF OR CD55 at 346-355 and may interact with
; OTHER INFORMATION: Sequence 3286 in this patent.

US-09-572-404B-3285

Query Match 2.5%; Score 52; DB 11; Length 10;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 346 NKGGTTSST 355

Db 1 NKGGTTSST 10

|||||

Db 1 NKGGTTSST 10

RESULT 14

US-09-572-404B-3193

; Sequence 3193, Application US/09572404B
; Publication No. US20030078374A1

; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd

; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent

; CURRENT APPLICATION NUMBER: US/09/572,404B

; CURRENT FILING DATE: 2000-05-17

; SOFTWARE: ProtPatent version 1.0

; SEQ ID NO 3197

; LENGTH: 10

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; OTHER INFORMATION: sequence located in DAF OR CD55 at 348-357 and may interact with
; OTHER INFORMATION: Sequence 3198 in this patent.

; NUMBER OF SEQ ID NOS: 4203
; SOFTWARE: ProtPatent version 1.0

; SEQ ID NO 3193

; LENGTH: 10

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; OTHER INFORMATION: sequence located in DAF OR CD55 at 348-357 and may interact with
; OTHER INFORMATION: Sequence 3194 in this patent.

US-09-572-404B-3193

Query Match 2.5%; Score 51; DB 11; Length 10;

Best Local Similarity 100.0%; Pred. No. 4.2e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 348 GSGTTSQTTR 357

Db 1 GSGTTSQTTR 10

|||||

Db 1 GSGTTSQTTR 10

RESULT 15

US-09-572-404B-3197

; Sequence 3197, Application US/09572404B
; Publication No. US20030078374A1

; GENERAL INFORMATION:
; APPLICANT: Proteom Ltd

; TITLE OF INVENTION: Complementary peptide ligands from the human genome
; FILE REFERENCE: Human patent

; CURRENT APPLICATION NUMBER: US/09/572,404B

; CURRENT FILING DATE: 2000-05-17

; NUMBER OF SEQ ID NOS: 4203

; SOFTWARE: ProtPatent version 1.0

; SEQ ID NO 3197

; LENGTH: 10

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; OTHER INFORMATION: sequence located in DAF OR CD55 at 348-357 and may interact with
; OTHER INFORMATION: Sequence 3198 in this patent.

US-09-572-404B-3197

Query Match 2.5%; Score 51; DB 11; Length 10;

Best Local Similarity 100.0%; Pred. No. 4.2e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 348 GSGTTSQTTR 357

Db 1 GSGTTSQTTR 10

|||||

Db 1 GSGTTSQTTR 10

Search completed: November 18, 2003, 07:48:17

Job time : 243 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:11 ; Search time 17 Seconds
(without alignments)
1053.951 Million cell updates/sec

Title: US-09-623-035-2

Perfect score: 2064

Sequence: 1 MTVARPSVPAALPLGELPR.....HTCFTLTGLTLVTWGLLT 381

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 1987

Minimum DB seq length: 6

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	40	1.9	27	1	TXA3 ANESU
2	39.5	1.9	23	1	NEU_LITCE
3	38	1.8	27	1	PFS1 DROFU
4	37	1.8	20	1	TENB ACTTE
5	37	1.8	25	1	SODC PAROL
6	36.5	1.8	27	1	CK2B CONBE
7	36	1.7	21	1	JAP2_RANJA
8	36	1.7	23	1	CP23_SPOER
9	36	1.7	30	1	AATC RABIT
10	36	1.7	30	1	TAT HVIZH
11	35	1.7	18	1	PPM2 LIMPO
12	35	1.7	20	1	TENA ACTTE
13	34.5	1.7	28	1	SLPI_LEIQH
14	34	1.6	23	1	PAP1_SPOEX
15	34	1.6	23	1	PAP2_SPOEX
16	34	1.6	23	1	PAP3_SPOEX
17	34	1.6	28	1	NXLI_BOUJA
18	33.5	1.6	13	1	BPPI_BOTJA
19	33.5	1.6	23	1	SCK1_TITCA
20	33.5	1.6	30	1	VARG_VITRA
21	33	1.6	25	1	AUS1_LITRA
22	33	1.6	29	1	VARE VIOAR
23	33	1.6	30	1	VARE VIOAR
24	32.5	1.6	26	1	CXO6 CONTU
25	32.5	1.6	26	1	NIFQ_ENTAG
26	32.5	1.6	27	1	ACH4 MOUSE
27	32.5	1.6	28	1	SCX2 BUTSI
28	32	1.6	12	1	CD11_LITXA
29	32	1.6	16	1	CXAA_CONPE
30	32	1.6	18	1	PPM1_LIMPO
31	32	1.6	21	1	GYRA_STRSH
32	32	1.6	22	1	LANM STRMU
33	32	1.6	23	1	ALL5_HORSE

RESULT 1
TXA3 ANESU
ID TXA3 ANESU STANDARD; PRT; 27 AA.
AC P01535;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Neurotoxin III (Toxin ATX-III)
OS Anemonia sulcata (Snake-locks sea anemone)
OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actiniaria;
OC Nynanthaeae; Actiniidae; Anemonia.
OX NCBI_TaxID=6108;
RN [1]
RP SEQUENCE.
RC TISSUE=Cnidoblast;
RX MEDLINE=78084776; PubMed=23311;
RA Martinez G., Kopeyan C., Schweitz H., Lazdunski M.;
RT "Toxin III from Anemonia sulcata: Primary structure.";
RL FEBS Lett. 84:247-252 (1977)
RN [2]
RP PRELIMINARY SEQUENCE.
RX MEDLINE=78044787; PubMed=21843;
RA Beress L., Wunderer G., Wachter E.;
RT "Amino acid sequence of toxin III from Anemonia sulcata.";
RL Hoppe-Seyler's Z. Physiol. Chem. 358:985-988 (1977)
RN [3]
RP STRUCTURE BY NMR.
RX MEDLINE=93343891; PubMed=8102051;
RA Norton R.S., Cross K., Braach-Maksvytis V., Wachter E.;
RT "1H-NMR study of the solution properties and secondary structure of neurotoxin III from the sea anemone Anemonia sulcata.";
RL Biochem. J. 293:545-551 (1993)
RN [4]
RP STRUCTURE BY NMR.
RX MEDLINE=95244415; PubMed=7727358;
RA Manoleras N., Norton R.S.;
RT "Three-dimensional structure in solution of neurotoxin III from the sea anemone Anemonia sulcata.";
RL Biochemistry 33:11051-11061 (1994)
CC -1- FUNCTION: BINDS SPECIFICALLY TO THE SODIUM CHANNEL.
CC -1- SUBCELLULAR LOCATION: Secreted; cnidocyst.
CC -1- SIMILARITY: BELONGS TO THE SEA ANEMONE SHORT TOXIN FAMILY.
DR PIR; A91446; T2A23.
DR PDB; 1ANS; 31-AUG-94.
KW Toxin; Neurotoxin; Ionic channel inhibitor; Sodium channel inhibitor;
FT DISULFID 3 17
FT DISULFID 4 11
FT DISULFID 6 22
FT CONFLICT 22 23 CS -> SC (IN REF. 2).
FT TURN 7 10
SQ SEQUENCE 27 AA; 2938 MW; AA4E261FFAF34A7A CRC64;

Query Match 1.9%; Score 40; DB 1; Length 27;
Best Local Similarity 26.7%; Pred. No. 3.5e+03;
Matches 8; Conservative 2; Mismatches 8; Indels 12; Gaps 1;

P24160 conus texti
P09355 apis mellif
P81798 echis multi
P58793 conus ermin
P04097 buthus occi
P31083 synechococc
P82230 viola odora
P80926 arachis hyp
P27459 achromobact
P16852 triticum ae
P83447 pseudananas
P11419 desulfovibr

ALIGNMENTS

34 32 1.6 27 1 CX7A CONTE
35 32 1.6 27 1 LSP APIME
36 32 1.6 29 1 MULR ECHML
37 32 1.6 30 1 CXVB CONER
38 31.5 1.5 24 1 SCXB BUTOC
39 31.5 1.5 29 1 PSAP_SNP6
40 31.5 1.5 30 1 CYOI_VIOOD
41 31 1.5 24 1 CS33 ARAHY
42 31 1.5 25 1 PRLA ACHLY
43 31 1.5 27 1 IAI7 WHEAT
44 31 1.5 27 1 MDO2_PSEMR
45 31 1.5 27 1 SODM_DESDE

```
QY 28 CLPAVWDCGLPDPVFNPAQALSGRTSFPE 57
DB 3 CCPCYMGCCPW-----GQNCYPE 20

RESULT 2
NEUU_LITCE STANDARD; PRT; 23 AA.
AC P81872;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Neuromedin U-23 (NMU-23).
OS Eukaria caerulea (Green tree frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Bufonoidea; Hylidae;
OC Pelodyadinae; Litoria.
OX NCBI_TaxID=30344;
RN [1]
RP SEQUENCE, AND SYNTHESIS.
RC TISSUE=Skin secretion;
RX MEDLINE=20138182; PubMed=10671478;
RA Salmon A.L., Johnsen A.H., Bienert M., McMurray G., Nandha K.A.,
RA Bloom S.R., Shaw C.;
RT "Isolation, structural characterization and bioactivity of a novel
RT neuromedin U analog from the defensive skin secretion of the
RT Australasian tree frog Litoria caerulea."
RL J. Biol. Chem. 275:4549-4554(2000).
CC -I- FUNCTION: STIMULATE UTERINE SMOOTH MUSCLE CONTRACTION AND CAUSE
CC SELECTIVE VASOCONSTRICTION.
CC -I- SUBCELLULAR LOCATION: Secreted.
CC -I- TISSUE SPECIFICITY: Skin.
CC -I- SIMILARITY: BELONGS TO THE NMU FAMILY.
DR InterPro: IPR001942; NMU.
DR Pfam: PF02070; NMU; 1.
DR PROSITE: PS00967; NMU; 1.
KW Amidation; Hormone.
FT MOD RES 23 23 AMIDATION.
SQ SEQUENCE 23 AA; 2581 MW; A94958415CB58DC3 CRC64;

Query Match 1.9%; Score 39.5; DB 1; Length 23;
Best Local Similarity 32.0%; Pred. No. 3.2e+03;
Matches 8; Conservative 5; Mismatches 3; Indels 9; Gaps 1;

QY 173 QIDVPGGILFGATISFCNTGYKLF 197
DB 4 EVQVPGGVI-----SNGYFLF 19

RESULT 3
PPS1_DROFU STANDARD; PRT; 27 AA.
AC P01372;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 01-OCT-1996 (Rel. 34, Last annotation update)
DE Paragonial peptide PS-1 (Paragonial peptide C).
GN PAPC.
OS Drosophila funebris (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7221;
RN [1]
RP SEQUENCE.
RX MEDLINE=77245908; PubMed=1236144;
RA Baumann H., Wilson K.J., Chen P.S., Humbel R.E.;
RT "The amino-acid sequence of a peptide (PS-1) from Drosophila
RT funebris: a paragonial peptide from males which reduces the
RT receptivity of the female."
RL Eur. J. Biochem. 52:521-529(1975).
CC -I- FUNCTION: REPRESSIONS FEMALE SEXUAL RECEPTIVITY AND STIMULATES
```

```
CC OVIPOSITION. THIS PEPTIDE HAS A LOW ACTIVITY.
CC -I- SUBCELLULAR LOCATION: Secreted.
CC -I- TISSUE SPECIFICITY: MAIN CELLS OF THE ACCESSORY GLANDS OF MALES
CC (PARAGONIAL GLAND).
DR PIR; A01643; PGFF1.
DR FlyBase; FBgn0004112; Dfun\PapC.
KW Behavior.
FT VARIANT 2 2 V -> L (IN 30% OF THE MOLECULES).
SQ SEQUENCE 27 AA; 2669 MW; D8083427974AD5D6 CRC64;

Query Match 1.8%; Score 38; DB 1; Length 27;
Best Local Similarity 26.9%; Pred. No. 4.8e+03;
Matches 7; Conservative 7; Mismatches 12; Indels 0; Gaps 0;

QY 303 NYPTEVSPTSQKTTTKTTTPNAQAT 328
DB 1 DVPSANANANNORTAAAKPQANAAS 26

RESULT 4
TENB_ACTTE STANDARD; PRT; 20 AA.
AC P30834;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Tenebrosin B (Fragment).
OS Actinia tenebrosa (Austrian red waratah sea anemone).
OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actiniaria;
OC Nynantheae; Actiniidae; Actinia.
OX NCBI_TaxID=6105;
RN [1]
RP SEQUENCE.
RX MEDLINE=90232538; PubMed=1970442;
RA Norton R.S., Bobek G., Ivanov J.O., Thomson M., Fiala-Beer E.,
RA Moritz R.L., Simpson R.J.;
RT "Purification and characterisation of proteins with cardiac
RT stimulatory and haemolytic activity from the anemone Actinia
RT tenebrosa."
RL Toxicol 28:29-41(1990).
CC -I- FUNCTION: This cardiac stimulatory and hemolytic protein is a
CC channel-forming and/or membrane-penetrating protein.
CC -I- SUBCELLULAR LOCATION: Secreted; Cnidocyst.
CC -I- SIMILARITY: BELONGS TO THE TENEBROSIN FAMILY.
DR PIR; B34016; B34016.
KW Cytolysis; Hemolysis; Toxin; Cnidocyst; Transmembrane.
FT NON TER 20 20
SQ SEQUENCE 20 AA; 1960 MW; FA32B426009FF5FA CRC64;

Query Match 1.8%; Score 37; DB 1; Length 20;
Best Local Similarity 37.5%; Pred. No. 4.1e+03;
Matches 6; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 174 IDVPGGILFGATISFS 189
DB 2 VAVAGAVIEGALTFFN 17

RESULT 5
SODC_PAROL STANDARD; PRT; 25 AA.
AC P83129;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Fragment).
OS Paralichthys olivaceus (Flounder).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Acanthomorpha; Acanthopterygii; Percomorpha; Pleuronectiformes;
OC Pleuronectoidae; Paralichthyidae; Paralichthys.
OX NCBI_TaxID=8255;
RN [1]
```

```

RP SEQUENCE, AND CHARACTERIZATION.
RC TISSUE=Hepatopancreas;
RX MEDLINE=21186415; PubMed=11290457;
RA Osatomi K., Masuda Y., Hara K., Iehihara T.;
RT "Purification, N-terminal amino acid sequence, and some properties of
RT Cu, Zn-superoxide dismutase from Japanese flounder (Paralichthys
RT olivaceus) hepato-pancreas.";
RL Comp. Biochem. Physiol. 128B:751-760(2001).
CC -!- FUNCTION: Destroys radicals which are normally produced within the
CC cells and which are toxic to biological systems (By similarity).
CC -!- CATALYTIC ACTIVITY: 2 superoxide + 2 H(+) = O(2) + H(2)O(2).
CC -!- COFACTOR: Binds 1 copper ion and 1 zinc ion per subunit (By
CC similarity).
CC -!- SUBUNIT: Homotrimer.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
CC -!- SIMILARITY: BELONGS TO THE CU-ZN SUPEROXIDE DISMUTASE
CC FAMILY.
DR GO: GO:0005737; C:cytoplasm; TAS.
DR GO: GO:0005507; F:copper ion binding activity; ISS.
DR GO: GO:0004785; F:copper, zinc superoxide dismutase activity; IDA.
DR GO: GO:0008270; F:zinc ion binding activity; ISS.
DR GO: GO:0019430; P:removal of superoxide radicals; TAS.
DR InterPro: IPR001424; SOD_CU_ZN.
DR Pfam: PF00800; sdcu; 1.
DR PROSITE: PS00087; SOD_CU_ZN_1; PARTIAL.
DR PROSITE: PS00332; SOD_CU_ZN_2; PARTIAL.
KW Antioxidant; Oxidoreductase; Metal-binding; Copper; Zinc.
FT NON_TER 25 25
SQ SEQUENCE 25 AA; 2604 MW; 76C4321D740857C5 CRC64;

Query Match 1.8%; Score 37; DB 1; Length 25;
Best Local Similarity 77.8%; Pred. No. 5.2e+03;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 347 KSGTSGT 355
DB 9 KGAGTSGT 17

RESULT 6
CX2B_CONBE STANDARD; PRT; 27 AA.
AC P81727;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Conotoxin BcXIIb.
OS Conus betulinus (Beech cone).
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;
OC Neogastropoda; Conoidea; Conidae; Conus.
OX NCBI_TaxID=89764;
[1]
RP SEQUENCE, MASS SPECTROMETRY, AND HYDROXYLATION.
RC TISSUE=Venom;
RX MEDLINE=20058566; PubMed=10591037;
RA Chen J.-S., Fan C.-X., Hu K.-P., Wei K.-H., Zhong M.-N.;
RT "Studies on conotoxins of Conus betulinus.";
RL J. Nat. Toxins 8:341-349(1999).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.
CC -!- MASS SPECTROMETRY: MW=2664.3; METHOD=MALDI.
CC -!- SIMILARITY: BELONGS TO THE P-SUPERFAMILY OF CONOTOXINS.
KW Neurotoxin; Toxin; Hydroxylation.
FT DISULFID 2 16 BY SIMILARITY.
FT DISULFID 6 19 BY SIMILARITY.
FT DISULFID 12 24 BY SIMILARITY.
FT MOD_RES 13 13 HYDROXYLATION.
SQ SEQUENCE 27 AA; 2651 MW; 60F0500514C7F1BA CRC64;

Query Match 1.8%; Score 36.5; DB 1; Length 27;
Best Local Similarity 44.4%; Pred. No. 6.1e+03;
Matches 8; Conservative 3; Mismatches 6; Indels 1; Gaps 1;

```

```

QY 178 GGI-LFGATISPSCNTGY 194
DB 3 GGVCAYGSCPSSCNTCY 20

RESULT 7
JAP2_RANJA STANDARD; PRT; 21 AA.
ID JAP2_RANJA STANDARD; PRT; 21 AA.
AC P83306;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Japonicin-2.
OS Rana japonica (Japanese reddish frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranioidea; Rana.
OX NCBI_TaxID=8402;
[1]
RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.
RC TISSUE=Skin secretion;
RX MEDLINE=21826910; PubMed=11835990;
RA Isaacson T., Soto A., Iwamuro S., Knoop F.C., Conlon J.M.;
RT "Antimicrobial peptides with atypical structural features from the
RT skin of the Japanese brown frog Rana japonica.";
RL Peptides 23:419-425(2002).
CC -!- FUNCTION: Antibacterial activity against the Gram-negative
CC bacterium E.coli and the Gram-positive bacterium S.aureus.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Skin.
CC -!- MASS SPECTROMETRY: MW=2685.4; METHOD=Electrospray.
KW Amphibian defense peptide; Antibiotic.
FT DISULFID 14 21 BY SIMILARITY.
SQ SEQUENCE 21 AA; 2358 MW; AB055DF897566BDF CRC64;

Query Match 1.7%; Score 36; DB 1; Length 21;
Best Local Similarity 46.7%; Pred. No. 5e+03;
Matches 7; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 12 LPPLGELPRLLLVL 26
DB 3 LPMLSILPKALCILL 17

RESULT 8
CP23_SPOER STANDARD; PRT; 23 AA.
ID CP23_SPOER STANDARD; PRT; 23 AA.
AC P56683;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Cardioactive peptide CAP23.
OS Spodoptera eridania (Southern armyworm).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Noctuoidea;
OC Noctuidae; Amphipyrae; Spodoptera.
OX NCBI_TaxID=37547;
[1]
RP SEQUENCE.
RX MEDLINE=99196260; PubMed=10098624;
RA Furiya K., Hackett M., Cirelli M.A., Schegg K.M., Wang H.,
RA Shabanowitz J., Hunt D.F., Schooley D.A.;
RT "A cardioactive peptide from the southern armyworm, Spodoptera
RT eridania.";
RL Peptides 20:53-61(1999).
CC -!- FUNCTION: HAS EXCITATORY EFFECTS ON A SEMI-ISOLATED HEART FROM
CC LARVAL MANDUCA SEXTA, CAUSING AN INOTROPIC EFFECT AT LOW
CC CONCENTRATIONS OF PEPTIDE AND CHRONOTROPIC AND INOTROPIC EFFECTS
CC AT HIGH DOSES.
CC -!- SIMILARITY: BELONGS TO THE GBP / PSP1 / PARALYTIC PEPTIDE FAMILY.
DR HSSP; 061704; 1B1V.
DR InterPro: IPR003463; GBP_PSP.
DR Pfam: PF02425; GBP_PSP; 1.

```

```

DR ProDom: PD006507; GBP_PSP: 1. BY SIMILARITY.
FT DISULFID 7 19
SQ SEQUENCE 23 AA; 2519 MW; 0A96D72A70855AE0 CRC64;

Query Match 1.7%; Score 36; DB 1; Length 23;
Best Local Similarity 47.1%; Pred. No. 5.5e+03;
Matches 8; Conservative 1; Mismatches 2; Indels 6; Gaps 1;

QY 119 FPGVTVEYECRPGYR 135
DB 3 FAVG-----CTPGYR 13

RESULT 9
AATC_RABIT STANDARD; PRT; 30 AA.
AC P12343;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Aspartate aminotransferase, cytoplasmic (EC 2.6.1.1) (Transaminase A)
DE (Glutamate oxaloacetate transaminase-1) (Fragment).
GN GOT1.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE.
RC TISSUE=Liver;
RX MEDLINE=85289123; PubMed=4030726;
RA Kuramitsu S., Inoue K., Kondo K., Aki K., Kagamiyama H.;
RT "Aspartate aminotransferase isozymes from rabbit liver. Purification
and properties.";
RL J. Biochem. 97:1337-1345(1985).
CC -!- CATALYTIC ACTIVITY: L-aspartate + 2-oxoglutarate = oxaloacetate +
L-glutamate.
CC -!- COFACTOR: Pyridoxal phosphate.
CC -!- SUBUNIT: Homodimer.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.
CC -!- MISCELLANEOUS: In eukaryotes there are cytoplasmic, mitochondrial
and chloroplastic isozymes.
CC -!- SIMILARITY: BELONGS TO CLASS-I OF PYRIDOXAL-PHOSPHATE-DEPENDENT
AMINOTRANSFERASES.
CC PIR; A27103; A27103.
DR HSSP; P00503; 1AJS.
DR InterPro; IPR004838; NHTransf 1.
DR PROSITE; PS00105; AA_TRANSFER_CLASS 1; PARTIAL.
KW Transferase; Aminotransferase; Pyridoxal phosphate.
FT NON_TER 30 30
SQ SEQUENCE 30 AA; 3296 MW; 9B76CBEAC2FC5D98 CRC64;

Query Match 1.7%; Score 36; DB 1; Length 30;
Best Local Similarity 42.3%; Pred. No. 7.4e+03;
Matches 11; Conservative 2; Mismatches 7; Indels 6; Gaps 2;

QY 39 PP-----DVNQAQPALGR--TSPED 58
DB 2 PPSIFAEVQAQPVLFKLTADPRD 27

RESULT 10
TAT_HV12H STANDARD; PRT; 30 AA.
AC P12512;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE TAT protein (transactivating regulatory protein) (Fragment).
GN TAT.
OS Human immunodeficiency virus type 1 (Zaire HZ321 isolate) (HIV-1).
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11692;

[1]
RN SEQUENCE FROM N.A.
RP MEDLINE=89228766; PubMed=2713163;
RA Srinivasan A., York D., Butler D. Jr., Jannoun-Nasr R., Getchell-J.,
RA McCormick J., Ou C.Y., Myers G., Smith T., Chen E.;
RT "Molecular characterization of HIV-1 isolated from a serum collected
RT in 1976; nucleotide sequence comparison to recent isolates and
RT generation of hybrid HIV.";
RL AIDS Res. Hum. Retroviruses 5:121-129(1989).
CC -!- FUNCTION: TRANSCRIPTIONAL REGULATOR THAT ACTS BY BINDING TO THE
CC TRANS-ACTIVATING RESPONSIVE SEQUENCE (TAR) RNA ELEMENT AND
CC ACTIVATES TRANSCRIPTION INITIATION AND/OR ELONGATION FROM THE LTR
CC PROMOTER.
CC -!- SUBUNIT: BINDS CYCLIN T1 (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Nuclear; nucleolar.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; M15896; AAB53949.1; -
DR HIV; M15896; TATS2321.
KW Transcription regulation; Activator; RNA-binding; Nuclear protein;
KW AIDS.
FT NON_TER 1 1
SQ SEQUENCE 30 AA; 3329 MW; 545F848858040A1F CRC64;

Query Match 1.7%; Score 36; DB 1; Length 30;
Best Local Similarity 43.8%; Pred. No. 7.4e+03;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 304 VPTTEVSPTSQKTTK 319
DB 2 LPTTRGNPTGPKESK 17

RESULT 11
PPM2_LIMPO STANDARD; PRT; 18 AA.
AC P14316;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-JAN-1990 (Rel. 13, Last sequence update)
DT 01-OCT-1994 (Rel. 30, Last annotation update)
DE Polyphephus II.
OS Limulus polyphemus (Atlantic horseshoe crab).
OC Eukaryota; Metazoa; Arthropoda; Chelicerata; Merostomata; Xiphosura;
OC Limulidae; Limulus.
OX NCBI_TaxID=6850;
RN [1]
RP SEQUENCE.
RA MEDLINE=90110066; PubMed=2514185;
RA Miyata T., Tokunaga F., Yonaga T., Yoshikawa K., Iwanaga S., Niwa M.,
RA Takao T., Shimonishi Y.;
RT "Antimicrobial peptides, isolated from horseshoe crab hemocytes,
RT tachyplesin II, and polyphesins I and II: chemical structures and
RT biological activity.";
RL J. Biochem. 106:663-668(1989).
CC -!- FUNCTION: SIGNIFICANTLY INHIBITS THE GROWTH OF GRAM-NEGATIVE AND
CC GRAM-POSITIVE BACTERIA.
CC -!- TISSUE SPECIFICITY: HEMOCYTES.
CC -!- SIMILARITY: BELONGS TO THE TACHYPLESIN/POLYPHEMUSIN FAMILY.
DR PIR; JU0125; JU0125.
KW Antibiotic; Amidation.
FT DISULFID 4 17 BY SIMILARITY.
FT DISULFID 8 13 BY SIMILARITY.
FT MOD_RES 18 18 AMIDATION.
SQ SEQUENCE 18 AA; 2431 MW; E402A109D2923504 CRC64;

Query Match 1.7%; Score 35; DB 1; Length 18;

```

Best Local Similarity 36.8%; Pred. No. 5e+03;
Matches 7; Conservative 1; Mismatches 3; Indels 8; Gaps 1;

QY 80 ICLGQWSDIEFCNRS 98
: : : : :
7 VCVKG-----FCYRK 17

Db

RESULT 12
TENA ACTTE
ID TENA ACTTE STANDARD; PRT; 20 AA.
AC P30833;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Tenebrosin A (Fragment).
OS Actinia tenebrosa (Australian red waratah sea anemone).
OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zoantharia; Actiniaria;
OC Nynanthaeae; Actiniidae; Actinia.
OX NCBI_TaxID=6105;
RN [1]
RP SEQUENCE.
RX MEDLINE=90232538; PubMed=1970442;
RA Norton R.S., Bobek G., Ivanov J.O., Thomson M., Fiala-Beer E.,
RA Moritz R.L., Simpson R.J.;
RT "Purification and characterisation of proteins with cardiac
stimulatory and haemolytic activity from the anemone Actinia
tenebrosa";
RL Toxicon 28:29-41(1990).
CC -!- FUNCTION: This cardiac stimulatory and hemolytic protein is a
channel-forming and/or membrane-penetrating protein.
CC -!- SUBCELLULAR LOCATION: Secreted; chidocyst.
CC -!- SIMILARITY: BELONGS TO THE TENEBROSIN FAMILY.
DR PIR; A34016; A34016.
KW Cytolysis; Hemolysis; Toxin; Chidocyst; Transmembrane.
FT NON_TER 20
SQ SEQUENCE 20 AA; 1974 MW; FA32AC8BDAAPF5FA CRC64;

Query Match 1.7%; Score 35; DB 1; Length 20;
Best Local Similarity 46.2%; Pred. No. 5.6e+03;
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 176 VFGGILFGATISF 188
: : : : :
4 VAGAVIEGATLTF 16

Db

RESULT 13
SLPI LEIQH
ID SLPI LEIQH STANDARD; PRT; 28 AA.
AC P80669;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Leuropeptide I.
OS Leiurus quinquestriatus hebraeus (Yellow scorpion).
OC Eukaryota; Metazoa; Arthropoda; Chelicerata; Arachnida; Scorpiones;
OC Euthoidea; Euthoidea; Leiurus.
OX NCBI_TaxID=6884;
RN [1]
RP SEQUENCE, AND STRUCTURE BY NMR.
RX TISSUE=Venom;
RC MEDLINE=97411504; PubMed=9266482;
RA Buissine E., Wieruzecki J.-M., Lippens G., Wouters D., Tartar A.,
RA Sautiere P.;
RT "Characterization of a new family of toxin-like peptides from the
venom of the scorpion Leiurus quinquestriatus hebraeus. 1H-NMR
structure of leuropeptide II.";
RL J. Pept. Res. 49:545-555(1997).
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -!- SIMILARITY: BELONGS TO THE SCORPION LEIUROTOXIN FAMILY.
DR HSSP; Q9NJPF; 1DU9.

KW Toxin.
FT DISULFID 3 19
FT DISULFID 6 24
FT DISULFID 10 26
SQ SEQUENCE 28 AA; 2954 MW; 5F72AD78BD39BE1B CRC64;

Query Match 1.7%; Score 34.5; DB 1; Length 28;
Best Local Similarity 39.1%; Pred. No. 8.7e+03;
Matches 9; Conservative 1; Mismatches 4; Indels 9; Gaps 2;

QY 220 CREIYCP-----APQIDNGI 235
: : : : :
3 CEE--CPMECKGKNAKPTCDNGV 23

Db

RESULT 14
PAP1 SPOEX
ID PAP1 SPOEX STANDARD; PRT; 23 AA.
AC P30255;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Paralytic peptide I (pp I).
OS Spodoptera exigua (Beet armyworm).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Noctuoidea;
OC Noctuidae; Amphipyridae; Spodoptera.
OX NCBI_TaxID=7107;
RN [1]
RP SEQUENCE.
RC TISSUE=Hemolymph;
RX MEDLINE=91302298; PubMed=2071576;
RA Skinner W.S., Dennis P.A., Li J.P., Summerfelt R.M., Carney R.L.,
RA Quistad G.B.;
RT "Isolation and identification of paralytic peptides from hemolymph of
the lepidopteran insects Manduca sexta, Spodoptera exigua, and
Heliothis virescens";
RL J. Biol. Chem. 266:12873-12877(1991).
CC -!- FUNCTION: CAUSES RAPID, RIGID PARALYSIS WHEN INJECTED INTO
LEPIDOPTERAN LARVAE. THE PHYSIOLOGICAL ROLE MAY BE TO REDUCE
HEMOLYPH LOSS FOLLOWING INJURY AND PROMOTE WOUND HEALING.
CC -!- SIMILARITY: BELONGS TO THE GBP / PSPI / PARALYTIC PEPTIDE FAMILY.
DR PIR; C39855; C39855.
DR HSSP; O61704; 1B1V.
DR InterPro; IPR003463; GBP_PSP.
DR Pfam; PF02425; GBP_PSP; 1.
DR ProDom; PD006507; GBP_PSP; 1.
KW Hemolymph.
FT DISULFID 7 19
SQ SEQUENCE 23 AA; 2451 MW; 0A96D1F600855AE0 CRC64;

Query Match 1.6%; Score 34; DB 1; Length 23;
Best Local Similarity 71.4%; Pred. No. 7.6e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 129 CRPGYRR 135
: : : : :
7 CTGPGQR 13

Db

RESULT 15
PAP2 SPOEX
ID PAP2 SPOEX STANDARD; PRT; 23 AA.
AC P30256;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Paralytic peptide II (pp II).
OS Spodoptera exigua (Beet armyworm).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Noctuoidea;
OC Noctuidae; Amphipyridae; Spodoptera.
OX NCBI_TaxID=7107;

```
RN [1]
RP SEQUENCE
RC TISSUE=Hemolymph;
RX MEDLINE=91302298; PubMed=2071576;
RA Skinner W.S.; Dennis P.A.; Li J.P.; Summerfelt R.M.; Carney R.L.;
RA Quistad G.B.;
RT "Isolation and identification of paralytic peptides from hemolymph of
RT the lepidopteran insects Manduca sexta, Spodoptera exigua, and
RT Heliothis virescens."
RL J. Biol. Chem. 266:12873-12877(1991).
CC -1- FUNCTION: CAUSES RAPID, RIGID PARALYSIS WHEN INJECTED INTO
CC LEPIDOPTERAN LARVAE. THE PHYSIOLOGICAL ROLE MAY BE TO REDUCE
CC HEMOLYMPH LOSS FOLLOWING INJURY AND PROMOTE WOUND HEALING.
CC -1- SIMILARITY: BELONGS TO THE GBP / PSP1 / PARALYTIC PEPTIDE FAMILY.
DR PIR; D39855; D39855.
DR HSP; O61704; IB1V.
DR InterPro; IPR003463; GBP_PSP.
DR Pfam; PF02425; GBP_PSP; 1.
DR ProDom; PD006507; GBP_PSP; 1.
KW Hemolymph.
FT DISULFID 7 19 BY SIMILARITY.
SQ SEQUENCE 23 AA; 2477 MW; 0A96CB4600855AE0 CRC64;

Query Match 1.6%; Score 34; DB 1; Length 23;
Best Local Similarity 71.4%; Pred. No. 7.6e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 129 CRFGYRR 135
Db | ||| |
7 CTGYQR 13
```

Search completed: November 18, 2003, 07:42:42
Job time : 19 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 18, 2003, 07:42:16 ; Search time 56 Seconds
(without alignments)

1755.679 Million cell updates/sec

Title: US-09-623-035-2

Perfect score: 2064

Sequence: 1 MVARPSVPAALPLLGELPR.....HTCFTLTGLLGLTVWMLLT 381

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 16438

Minimum DB seq length: 6

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_23:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phase:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_rvirus:*
- 16: sp_bacteriap:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	48	2.3	30	5 Q27545	Q27545 crithidia f
2	45.5	2.2	25	6 Q9BG19	Q9BG19 cheirogaleu
3	44.5	2.2	22	11 Q9RIC1	Q9RIC1 mus musculu
4	43	2.1	29	15 Q71992	Q71992 human endog
5	40.5	2.0	20	4 Q96T45	Q96T45 homo sapien
6	40.5	2.0	26	11 Q9JMC5	Q9JMC5 rattus norv
7	40.5	2.0	30	11 Q9QV95	Q9QV95 cavia (guin
8	40	1.9	20	3 Q9URC1	Q9URC1 phanerochae
9	40	1.9	27	13 Q57555	Q57555 lampetra pl
10	40	1.9	27	13 Q57554	Q57554 lampetra pl
11	40	1.9	30	11 Q9JK06	Q9JK06 mus musculu
12	39.5	1.9	26	5 Q8N066	Q8N066 plasmodium
13	39	1.9	25	6 Q9BGJ0	Q9BGJ0 eulemur mac
14	39	1.9	27	12 Q9IJ66	Q9IJ66 hepatitis c
15	39	1.9	28	6 Q9XS67	Q9XS67 bos taurus
16	39	1.9	30	13 Q9PRP7	Q9PRP7 echis carin

17	38.5	1.9	30	13	Q9PRP8	Q9PRP8 echis carin
18	38	1.8	19	6	Q8MJ41	Q8MJ41 bos taurus
19	38	1.8	23	11	Q64014	Q64014 mus sp. inh
20	38	1.8	23	11	Q9R231	Q9R231 rattus norv
21	38	1.8	24	16	Q9K8M1	Q9K8M1 bacillus ha
22	38	1.8	25	12	O11469	O11469 hepatitis c
23	38	1.8	26	6	Q9TRM6	Q9TRM6 bos taurus
24	38	1.8	27	5	Q23745	Q23745 ctenodrilus
25	38	1.8	30	4	Q96D69	Q96D69 homo sapien
26	37.5	1.8	25	2	O07916	O07916 mycobacteri
27	37.5	1.8	26	10	Q9S8H2	Q9S8H2 secale cere
28	37.5	1.8	27	12	Q9QIB5	Q9QIB5 hepatitis c
29	37.5	1.8	27	12	Q9QIC1	Q9QIC1 hepatitis c
30	37.5	1.8	27	12	Q9QIB3	Q9QIB3 hepatitis c
31	37.5	1.8	27	12	Q9QIB9	Q9QIB9 hepatitis c
32	37.5	1.8	27	12	Q9QIB2	Q9QIB2 hepatitis c
33	37.5	1.8	27	12	Q9QIC7	Q9QIC7 hepatitis c
34	37.5	1.8	27	12	Q9QIB6	Q9QIB6 hepatitis c
35	37.5	1.8	27	12	Q9QIC6	Q9QIC6 hepatitis c
36	37.5	1.8	27	12	Q9QIB0	Q9QIB0 hepatitis c
37	37.5	1.8	27	12	Q9QIB4	Q9QIB4 hepatitis c
38	37.5	1.8	27	12	Q9QIC4	Q9QIC4 hepatitis c
39	37.5	1.8	27	12	Q9QIB7	Q9QIB7 hepatitis c
40	37.5	1.8	27	12	Q9QIC0	Q9QIC0 hepatitis c
41	37.5	1.8	27	12	Q9QIC9	Q9QIC9 hepatitis c
42	37.5	1.8	27	12	Q9QIB8	Q9QIB8 hepatitis c
43	37.5	1.8	27	12	Q9QIC5	Q9QIC5 hepatitis c
44	37.5	1.8	30	12	Q9QS21	Q9QS21 hepatitis b
45	37.5	1.8	30	12	Q9QS15	Q9QS15 hepatitis b

ALIGNMENTS

RESULT 1

Q27545 PRELIMINARY; PRT; 30 AA.
 AC Q27545;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)
 DE Reiske iron-sulfur protein precursor (EC 1.10.2.2) (Fragment).
 OS Crithidia fasciculata.
 OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Crithidia.
 OX NCBI_TaxID=5656;
 RN [1]_TaxID=5656;
 RP SEQUENCE FROM N.A.
 RX MEDLINE=96096683; PubMed=7495871;
 RA Priest J.W., Hajduk S.L.;
 RT "The trypanosomatid Reiske iron-sulfur proteins have a cleaved
 RT presequence that may direct mitochondrial import.";
 RL Biochim. Biophys. Acta 1269:201-204(1995).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93015890; PubMed=1328195;
 RA Priest J.W., Hajduk S.L.;
 RT "Cytochrome c reductase purified from Crithidia fasciculata contains
 RT an atypical cytochrome c.";
 RL J. Biol. Chem. 267:20188-20195(1992).
 DR EMBL; U28865; AAA89057.1; -;
 KW Mitochondrion; Oxidoreductase; Transit peptide.
 FT TRANSIT 1 17 MITOCHONDRION.
 FT CHAIN 18 >30 REISKE IRON-SULFUR PROTEIN.
 FT NON_TER 30 30
 SQ SEQUENCE 30 AA; 3399 MW; DE41365941814501 CRC64;

Query Match 2.3%; Score 48; DB 5; Length 30;

Best Local Similarity 44.4%; Pred. No. 2.2e+03;

Matches 12; Conservative 2; Mismatches 13; Indels 0; Gaps 0;

QY 319 KTTTNAQATRTSPVSRRTTKHFHTTP 345

Db 4 RTFTAFQATRAARVSLVVKLEGTTP 30

```

RESULT 2
Q9BG19 ID Q9BG19 PRELIMINARY; PRT; 25 AA.
AC Q9BG19;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DE ATP synthase beta subunit (Fragment).
OS Cheirogaleus medius (Fat-tailed dwarf lemur).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Strepsirhini; Cheirogaleidae;
OC Cheirogaleus.
OX NCBI_TaxID=9460;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21100352; PubMed=11156996;
RA Schmitz J., Ohme M., Zischler H.;
RT "SINE Insertions in Cladistic Analyses and the Phylogenetic
RT Affiliations of Tarsius bancanus to Other Primates.";
RL Genetics 157:777-784(2001).
DR EMBL; AF278741; AAK13316.1; -.
FT NON_TER 1 1
FT NON_TER 25 25
SQ SEQUENCE 25 AA; 2924 MW; 4D23CB57E8C2A4B CRC64;

Query Match 2.2%; Score 45.5; DB 6; Length 25;
Best Local Similarity 47.8%; Pred. No. 2.9e+03;
Matches 11; Conservative 4; Mismatches 5; Indels 3; Gaps 1;

QY 14 LIGEL---PRELLLVLLCLPAVW 33
Db 3 LMGEVPSKNNLLFLMLRLNLW 25

RESULT 3
Q9R1C1 ID Q9R1C1 PRELIMINARY; PRT; 22 AA.
AC Q9R1C1;
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DE Decay accelerating factor (Fragment).
GN DAF.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=BALB/c;
RX MEDLINE=99348049; PubMed=10417349;
RA Harris C.L., Rushmere N.K., Morgan B.P.;
RT "Molecular and functional analysis of mouse decay accelerating
RT factor.";
RL Biochem. J. 341:821-829(1999).
DR EMBL; AF143541; AAD51449.1; -.
FT NON_TER 1 1
FT NON_TER 22 22
SQ SEQUENCE 22 AA; 2371 MW; 3DAD8BF3A02D33DB CRC64;

Query Match 2.2%; Score 44.5; DB 11; Length 22;
Best Local Similarity 54.5%; Pred. No. 3e+03;
Matches 12; Conservative 1; Mismatches 8; Indels 1; Gaps 1;

QY 361 GHTC-ETLGLGLTGLTVMGLT 381
Db 1 GHTCLITLTVLHAWLSLIGLYT 22

RESULT 4
Q71992 ID Q71992 PRELIMINARY; PRT; 29 AA.

```

```

AC Q71992;
DT 01-AUG-1998 (TREMBlrel. 07, Created)
DT 01-AUG-1998 (TREMBlrel. 07, Last sequence update)
DE Reverse transcriptase (Fragment).
OS Human endogenous retrovirus.
OC Viruses; Retroviral viruses; Retroviridae.
OX NCBI_TaxID=11827;
RN [1]
RP SEQUENCE FROM N.A.
RX Rose T., Schultz E.R., Henikoff J.G., Pietrokovski S., McCallum C.M.,
RA Henikoff S.;
RT "Consensus-degenerate hybrid oligonucleotide primers for amplification
RT of distantly-related sequences.";
RL Nucleic Acids Res. 0:0-0(1998).
DR EMBL; AF050505; AAC05560.1; -.
FT NON_TER 1 1
FT NON_TER 29 29
SQ SEQUENCE 29 AA; 3303 MW; CD65212FB4DB04AB CRC64;

Query Match 2.1%; Score 43; DB 15; Length 29;
Best Local Similarity 40.9%; Pred. No. 5.8e+03;
Matches 9; Conservative 3; Mismatches 8; Indels 2; Gaps 1;

QY 109 LKQPYITONYFPVGTVEYECR 130
Db 1 LNSPTICQTY--VGQAIEFTCK 20

RESULT 5
Q96T45 ID Q96T45 PRELIMINARY; PRT; 20 AA.
AC Q96T45;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE MER receptor tyrosine kinase (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20517330; PubMed=11062461;
RA Gal A., Li Y., Thompson D.A., Weir J., Orth U., Jacobson S.G.,
RA Apfelstedt-Sylla E., Vollrath D.;
RT "Mutations in MERTK, the human orthologue of the RCS rat retinal
RT dystrophy gene, cause retinitis pigmentosa.";
RL Nat. Genet. 26:270-271(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX Gal A., Li Y., Thompson D.A., Weir J., Orth U., Jacobson S.G.,
RA Apfelstedt-Sylla E., Vollrath D.;
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF366903; AAK54121.1; -.
KW Kinase; Receptor.
FT NON_TER 20 20
FT NON_TER 20 20
SQ SEQUENCE 20 AA; 2232 MW; A853BEF7BEECE2910 CRC64;

Query Match 2.0%; Score 40.5; DB 4; Length 20;
Best Local Similarity 44.0%; Pred. No. 6e+03;
Matches 11; Conservative 2; Mismatches 3; Indels 9; Gaps 1;

QY 9 PAALPLLGELPRLLLVLLCLPAVW 33
Db 3 PAPLP-----LLGLFLPALW 18

RESULT 6
Q9JMC5 ID Q9JMC5 PRELIMINARY; PRT; 26 AA.
AC Q9JMC5;
DT 01-OCT-2000 (TREMBlrel. 15, Created)

```

```

DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update).
DE 01-OCT-2000 (TrEMBLrel. 15, Last annotation update)
DD Decay-accelerating factor (Fragment).
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OM Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RR SEQUENCE FROM N.A.
RP RP MEDLINE=20130146; PubMed=106633575;
RX Miwa T., Okada N., Okada H.;
RT "Alternative exon usage in the 3' region of a single gene generates
RD glycosylphosphatidylinositol-anchored and transmembrane forms of rat
RE decay-accelerating factor."
RL Immunogenetics 51:129-137(2000).
DR EMBL; AB032396; BAA92772.1; -.
FT NON_TER 1
FT NON_TER 26
FT NON_TER 26
SQ SEQUENCE 26 AA; 2906 MW; 9EDAE86206401B3 CRC64;

Query Match      2.0%; Score 40.5; DB 11; Length 26;
Best Local Similarity 34.6%; Pred.No. 8.4e+03;
Matches 9; Conservative 7; Mismatches 9; Indels 1; Gaps 1;

QY 328 TRSTPVSRTT-KHPHETPNKSGTT 352
Db 1 TOHPVSKTTVRHPTRTSKORGESNS 26
   : |||::||:| | |: ::| :
   : |||::||:| | |: ::| :

RESULT 7
ID Q9QV95 PRELIMINARY; PRT; 30 AA.
AC Q9QV95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DD 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE Organ of Corti protein (Fragment).
OS Cavia (guinea pigs).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OM Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae.
OX NCBI_TaxID=10140;
RN [1]
RR SEQUENCE.
RP RP MEDLINE=93163013; PubMed=8432690;
RX Thalmann I., Suzuki H., McCourt D.W., Comegys T.H., Thalmann R.;
RT "Partial amino acid sequences of organ of Corti proteins OCP1 and
RD OCP2: a progress report.";
RL Hear. Res. 64:191-198(1993).
DR InterPro; IPRO01810; F-box.
DR PROSITE; PS0181; FBOX; 1.
SQ SEQUENCE 30 AA; 3241 MW; 522DC63FFF68A8FC CRC64;

Query Match      2.0%; Score 40.5; DB 11; Length 30;
Best Local Similarity 66.7%; Pred.No. 1e+04;
Matches 12; Conservative 0; Mismatches 5; Indels 1; Gaps 1;

QY 15 LGELPRLLLVLLC-LPA 31
Db 4 LAELPEALLRLLAQLFA 21
   : ||| | | | | | | |
   : ||| | | | | | | |

RESULT 8
Q9URC1 PRELIMINARY; PRT; 20 AA.
ID Q9URC1
AC Q9URC1;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DD 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE 1,4-beta-D-glucan glucanohydrolase (EC 3.2.1.4) (Fragment).
OS Phanerochaete chrysosporium.
OC Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Homobasidiomycetes;
OM Aphyllorales; Corticiaceae; Phanerochaete.
OX NCBI TaxID=5306;

```

```
Query Match 1.9%; Score 40; DB 13; Length 27;
Best Local Similarity 72.7%; Pred. No. 9.7e+03;
Matches 8; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 42 VPNAQPALEGR 52
DB 5 VPDAGPALGR 15

RESULT 11
Q9JK06 PRELIMINARY; PRT; 30 AA.
AC Q9JK06
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Fructose-1,6-bisphosphatase (EC 3.1.3.11) (Fragment).
GN FBP2 OR FBPA2.2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RX MEDLINE=20237676; PubMed=10773464;
RA Tillmann H., Stein S., Liehr T., Eschrich K.;
RT "Structure and chromosomal localization of the human and mouse muscle
fructose-1,6-bisphosphatase genes.";
RL Gene 247:241-253(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RA Stein S.;
RT "Mouse liver fructose-1,6-bisphosphatase: Gene structure,
transcriptional start point, chromosomal localization, cDNA cloning,
RT characterization of the recombinant protein, and analysis of tissue-
specific expression.";
RL Arch. Biochem. Biophys. 0:0-0(0).
DR EMBL; AJ243023; CAB90670.1; -.
DR HSSP; P00637; 1BK4.
DR MGD; MGI:95491; Fbp2.
DR InterPro; IPR000146; In_FB_phptase.
DR Pfam; PF00316; FBPAse; 1.
DR ProDom; PD001491; In_FB_phptase; 1.
KW Hydrolase.
FT NON_TER 1 1
FT NON_TER 30 30
SQ SEQUENCE 30 AA; 3014 MW; 55146C35C817E0C1 CRC64;

Query Match 1.9%; Score 40; DB 11; Length 30;
Best Local Similarity 42.1%; Pred. No. 1.1e+04;
Matches 8; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 193 GYKLFQSTSSFCUIGSSV 211
DB 5 GYALYGSATLVALSTGGV 23

RESULT 12
Q8N066 PRELIMINARY; PRT; 26 AA.
AC Q8N066;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE BAEBL (Fragment).
GN BAEBL.
OS Plasmodium falciparum.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=5833;
RN [1]
RP SEQUENCE FROM N.A.
```

```
RX MEDLINE=21996440; PubMed=12000842;
RA Blair P.L., Witney A., Haynes J.D., Moch J.K., Carucci D.J.,
RA Adams J.H.;
RT "Transcripts of developmentally regulated Plasmodium falciparum genes
RT quantified by real-time RT-PCR.";
RL Nucleic Acids Res. 30:2224-2231(2002).
DR EMBL; AF461093; AAM33517.1; -.
FT NON_TER 1 1
FT NON_TER 26 26
SQ SEQUENCE 26 AA; 3020 MW; D8C1933CAEB37D17 CRC64;

Query Match 1.9%; Score 39.5; DB 5; Length 26;
Best Local Similarity 29.6%; Pred. No. 1e+04;
Matches 8; Conservative 5; Mismatches 9; Indels 5; Gaps 1;

QY 253 CNKGFTMIGEHSIYCTVNDEGEWSGP 279
DB 4 CNNEYSM-----EYCTYSDESNSSPGP 25

RESULT 13
Q9BGJ0 PRELIMINARY; PRT; 25 AA.
AC Q9BGJ0;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE ATP synthase beta subunit (Fragment).
OS Eulemur macaco macaco (Black lemur).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Strepsirhini; Lemuridae; Eulemur.
OX NCBI_TaxID=30603;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21100352; PubMed=11156996;
RA Schmitz J., Ohme M., Zischler H.;
RT "SINE Insertions in Cladistic Analyses and the Phylogenetic
RT Affiliations of Tarsius bancanus to Other Primates.";
RL Genetics 157:777-784(2001).
DR EMBL; AF278740; AAK13315.1; -.
FT NON_TER 1 1
FT NON_TER 25 25
SQ SEQUENCE 25 AA; 3023 MW; 4DE23CB5658D9A4B CRC64;

Query Match 1.9%; Score 39; DB 6; Length 25;
Best Local Similarity 53.3%; Pred. No. 1.1e+04;
Matches 8; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

QY 19 PRELLLVLLCLPAVW 33
DB 11 PNNLLFLRLPLNW 25

RESULT 14
Q9IJ66 PRELIMINARY; PRT; 27 AA.
AC Q9IJ66;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Envelope protein (genome polypeptide) (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Alberto S.-F.;
RT "Influence of the dynamics of Hepatitis C virus quasispecies in the
RT histological outcome of liver transplantation.";
RL Submitted (JAN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF221229; AAF7791.1; -.
InterPro; IPR002531; HCV_NSI.
```

```
DR Pfam; PF01560; HCV NS1; 1.  
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;  
KW Polyprotein; Transmembrane.  
FT NON_TER 1 1  
FT NON_TER 27 27  
SQ SEQUENCE 27 AA; 2776 MW; CA21BB0A7FB6C40B CRC64;  
  
Query Match 1.9%; Score 39; DB 12; Length 27;  
Best Local Similarity 50.0%; Pred. No. 1.2e+04;  
Matches 10; Conservative 0; Mismatches 6; Indels 4; Gaps 1;  
  
QY 352 TSGTTRLLSGHTCFILTLGL 371  
Db 4 TGGTV----GHNTFRLTSL 19  
  
RESULT 15  
Q9XS67  
ID Q9XS67 PRELIMINARY; PRT; 28 AA.  
AC Q9XS67;  
DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
DT 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)  
DE Very low density lipoprotein receptor (Fragment).  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidae;  
OC Bovidae; Bovinae; Bos.  
OX NCBI_TaxID=9913;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=99018030; PubMed=9799803;  
RA Magrane J., Reina M., Pagan R., Luna A., Casaroli-Marano R.P.,  
RA Angelin B., Gafvels M., Vilaro S.;  
RT "Bovine aortic endothelial cells express a variant of the very low  
RT density lipoprotein receptor that lacks the O-linked sugar domain."  
RL J. Lipid Res. 39:2172-2181(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=99283875; PubMed=10356983;  
RA Magrane J., Casaroli-Marano R.P., Reina M., Gafvels M., Vilaro S.;  
RT "The role of O-linked sugars in determining the very low density  
RT lipoprotein receptor stability or release from the cell."  
RL FEBS Lett. 451:56-62(1999).  
DR EMBL; AF034420; AAD31591.1; --  
KW Lipoprotein; Receptor.  
FT NON_TER 1 1  
FT NON_TER 28 28  
SQ SEQUENCE 28 AA; 2855 MW; A407207D44718A54 CRC64;  
  
Query Match 1.9%; Score 39; DB 6; Length 28;  
Best Local Similarity 47.4%; Pred. No. 1.3e+04;  
Matches 9; Conservative 2; Mismatches 8; Indels 0; Gaps 0;  
  
QY 295 TVQKPTTVNVPTTEVSPTS 313  
Db 4 TVVNETKDTNTAEISPTS 22
```

Search completed: November 18, 2003, 07:49:22
Job time : 58 secs

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)